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Abstract

KCC2: a novel therapeutic target to rescue GABAergic dysfunction and behavioral
deficits induced by HIV and opiate use

By Aaron J. Barbour
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2020

Major Director: Pamela E. Knapp, Professor
Department of Anatomy & Neurobiology

With adherence to combined antiretroviral therapy (cART), HIV infection can be
considered a controllable chronic condition, but quality of life issues remain. The
preeminent of which, HIV-associated neurocognitive disorders (HAND), encompasses an
array of neurological complications and has persisted despite cART implementation. The
symptoms of HAND can be exacerbated by opiate use, a common comorbidity for people
infected with HIV (PWH). While neurons are not infected by HIV, they incur sublethal
damage, with γ-amino butyric acid- (GABA)ergic function being particularly vulnerable to
viral and inflammatory factors released by infected/affected glia. This dissertation
presents studies on novel organoid and dissociated primary human CNS models of
HAND, the latter of which showed diminished levels of K+ - Cl- cotransporter 2 (KCC2), a
neuronal transporter that maintains low intracellular Cl-, after exposure to HIV-1 and HIV
proteins ± morphine. GABAAR-mediated hyperpolarization is predicated upon activity of
KCC2 and functional examination of these neurons revealed decreased hyperpolarization
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and disinhibition in response to GABAAR activation due KCC2 loss. Additionally, we
identified the mechanisms through which HIV-1 mediates KCC2 reduction: the HIV
protein, transactivator of transcription (Tat), through activation of N-methyl-D-aspartate
receptor (NMDAR), and the HIV protein, glycoprotein 120 (gp120), through a novel
mechanism involving CCR5 activation. We also found that morphine acts through the µ
opioid receptor (MOR) to dysregulate KCC2. Pharmacological maintenance of KCC2 with
the KCC2 enhancer, CLP257, rescued HIV, Tat, and morphine effects on KCC2 and
GABAAR activity.
Common neurological deficits in PWH include memory and motor dysfunction which are
likely the manifestations of HIV-induced hippocampal and striatal degeneration. Thus, we
expanded our in vitro results to the glial fibrillary acidic protein (GFAP)-driven,
doxycycline(DOX)-inducible Tat-transgenic mouse model of HAND. No changes in KCC2
in the hippocampus were seen, but we did find significant Tat-induced loss of KCC2 in
the striatum which was associated with locomotor abnormalities in these mice. We also
rescued phosphorylation of serine 940-KCC2 leading to increased KCC2 membrane
localization and restoration of baseline motor activity with oral gavage of the prodrug of
CLP257, CLP290. Overall, our in vitro and in vivo results demonstrate KCC2 as a
promising, novel therapeutic target to alleviate the symptoms associated with HAND ±
opiate use.
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Chapter 1: Introduction

The human immunodeficiency virus (HIV)

Worldwide, 37.9 million people are infected with HIV with 1.7 million new infections
in 2018 (UNAIDS, 2019). HIV infects cells of the immune system and can lead to nadir Tcell counts below 200, a point at which someone is classified as having acquired
immunodeficiency syndrome (AIDS). Both HIV subtypes (HIV-1, -2) are members of the
lentivirus genus within the retrovirus family. HIV-1 is more transmissible and more
prevalent worldwide than HIV-2 and is the focus of this dissertation. Four strains of HIV1 have been identified: M, O, N, and P. The most prevalent is strain M, which consists of
10 clades (A, B, C, D, F, G, H, J, K), and circulating recombinant forms with clade B being
the most prevalent subtype in America, Europe, and Australia (Gilbert et al., 2007).
HIV was first found to be the virus that causes AIDS in 1983 (Gallo et al., 1983)
and later found to be derived from simian immunodeficiency virus (Gao et al., 1999,
Bailes et al., 2003, Chen et al., 1997). Initial cases were found in vulnerable communities
including homosexual men (Brennan and Durack, 1981), injection drug users (CDC,
1982b), and hemophiliacs (CDC, 1982a), reflecting the modes of HIV transmission. HIV
can be passed through venous injection or exposure of mucous membrane or damaged
tissue to certain bodily fluids (blood, semen, rectal fluids, vaginal fluids, and breast milk)
of someone infected with HIV. Thus, HIV is most commonly transmitted by sexual
intercourse and needle sharing. Initial treatments for HIV-infection primarily consisted of
prophylaxis against opportunistic infections that arose due to reduced immune
competence (CDC, 1997, Moore and Chaisson, 1996). Combined antiretroviral therapy
3

(cART), became the recommended treatment for HIV/AIDS patients in 1997 and
dramatically shifted the progression of HIV (Gulick et al., 1997, Hammer et al., 1997,
Moore and Chaisson, 1999). The World Health Organization estimates that 62% of PWH
now have access to cART, which involves the administration of three or more
antiretrovirals (ARVs) simultaneously. ARVs are designed to interfere with each stage in
the life cycle of HIV. Until 2015, it was recommended to begin HIV+ patients on a cART
regimen after their cluster of differentiation (CD) 4 count dropped below 350 cells/mL, but
this was revised to begin cART as early as possible (UNAIDS, 2016). Implementation of
cART dramatically reduced viral replication and the viral load in many patients’ plasma to
undetectable levels (<50 RNA copies/mL) and reduced the mortality rate of HIV by 50 –
80% in the first ten years of use (Delaney, 2006).
HIV structure and life cycle
The HIV membrane is comprised of a lipid bilayer and proteins crucial for binding
and fusion with host cells, namely, glycoprotein 120 (gp120) and glycoprotein 41 (gp41).
The core of the HIV virion houses the viral genome, two single stranded RNA molecules,
and the viral proteins reverse transcriptase (RT) and integrase (IN) (Briggs et al., 2006).
Following mucosal invasion via interactions with dendritic cells (Turville et al., 2005,
Turville et al., 2004), HIV-1 has six major steps in its life cycle and, thus, there are six
major classes of ARVs: (1) binding/fusion (entry inhibitors), (2) reverse transcription
(Nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs)), (3) integration (integration inhibitors (INIs)), (4)
transcription/translation, (5) budding, and (6) proteolysis/maturation (protease inhibitors
(PIs)). Viral entry is initiated with binding of the viral coat protein, gp120, to CD4, found
4

primarily on helper T cells and macrophages/monocytes. Bound gp120 induces a
conformational change, exposing a binding site for either C-C chemokine receptor type 5
(CCR5) or C-X-C chemokine receptor type 4 (CXCR4) co-receptors, introducing the
different tropisms of HIV (Alkhatib et al., 1996, Deng et al., 1996, Feng et al., 1996, Trkola
et al., 1996). CCR5-tropic strains (R5-tropic) are the predominant HIV-1 strains for active
transmission and replication and preferentially bind CCR5 receptors found on
macrophages, monocytes and T-cells (Roos et al., 1992, Zhu et al., 1993, Schweighardt
et al., 2004) and are the most common type detected in the brain (Strizki et al., 1996,
Cunningham et al., 1997, Gorry et al., 2001). Some variants may shift co-receptor
preference to CXCR4 (X4-tropic variants) found on T-cells at later stages of infection (Ho
et al., 2007, Tasca et al., 2008, Ribeiro et al., 2006). Engagement of the co-receptor leads
to a conformational change in gp41, fusing the viral and host membranes to allow for the
insertion of the viral core. Entry inhibitors (maraviroc (MVC) and efurvitide) block the
actions of gp120/gp41 to prevent CD4/co-receptor binding and viral and host membrane
fusion. MVC is a CCR5 antagonist; efuvirtide binds gp41 preventing membrane fusion.
After membrane fusion, partial uncoating of the capsid proteins of the core occurs,
providing RT access to host deoxyribonucleoside triphosphates (dNTPs) to initiate
reverse transcription of viral RNA to cDNA, while forming the pre-integration complex
which can pass through the intact nuclear envelope (Forshey et al., 2002). NRTIs and
NNRTIs target reverse transcription to halt the virus life cycle. NRTIs are analogs of
dNTPs that can enter the catalytic site of RT; NNRTIs are allosteric modulators of RT
(Sarafianos et al., 1999, Huang et al., 1998). Both inhibit RT activity, preventing
conversion of viral RNA to cDNA. Host enzymes complete integration by repairing the
5

single strand gaps resulting in the HIV provirus, which can remain latent indefinitely (Folks
et al., 1986), which is a feature common to lentiviruses. Activation of immune cells by the
transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)
or nuclear factor of activated T-cells induce low level transcription of the integrated viral
DNA from the U3 promoter located in the upstream long terminal repeat (LTR) (Nabel
and Baltimore, 1987, Siekevitz et al., 1987, Duh et al., 1989, Kinoshita et al., 1998).
Transactivator of transcription (Tat) and Rev are the first proteins transcribed and
translated. Tat is necessary for efficient transcription of other viral proteins. Tat recruits
the host cellular protein transcription elongation factor-b (p-TEFb) to viral transactivation
response element (TAR) to enhance the activity of host RNA polymerase II (Tahirov et
al., 2010, Barboric et al., 2001). Viral mRNAs are produced as numerous alternate splice
forms. Smaller viral mRNAs can be transported directly out of the nucleus, while larger
species require Rev binding of Rev response element on the env protein to create a
nuclear export sequence (Daugherty et al., 2010). Once in the cytoplasm, viral mRNAs
are translated into immature polypeptides by host machinery. Viral proteins congregate
on the cellular membrane and begin to bud off of the host cell (Briggs et al., 2009, Carlson
et al., 2010). Concurrent with or directly after budding, HIV-1 protease cleaves the
immature polypeptides into mature proteins resulting in a mature infective virion (Pettit et
al., 1994, de Marco et al., 2010). PIs do not affect the ability of HIV to replicate and escape
host cells it has already infected, but do prevent affected virion from infecting new cells
(Kohl et al., 1988).
HIV-associated neurocognitive disorders
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Snider et al. (Snider et al., 1983) found that neurological impairments accompany
AIDS. Early investigations of this phenomenon discovered encephalopathy in many HIV
patients, demonstrating that HIV can harm the CNS (Masliah et al., 1992, Shaw et al.,
1985). Neurological impairments can range from asymptomatic (ANI) to HIV-associated
dementia (HAD), collectively termed HIV-associated neurocognitive disorders (HAND).
Affected neurological domains from HIV damage can include verbal/language ability,
attention/working memory, executive function, memory, speed of information processing,
sensory perception, and motor skills (Antinori et al., 2007). ANI and mild neurocognitive
impairment (MNI) are diagnosed as impairment in two cognitive domains with and without
impairment to daily life activities, respectively. HAD requires marked impairment in two or
more domains with significant daily functional impairment (Antinori et al., 2007, Saylor et
al., 2016). While the introduction of cART has reduced the prevalence of HAD, ANI and
MNI have increased with an overall prevalence of HAND remaining stable (Heaton et al.,
2010). While effective cART can reduce HIV to nondetectable levels in the periphery
(Autran et al., 1997, Komanduri et al., 1998, Lederman et al., 1998), the brain can act as
a reservoir of HIV, which may be implicated in the persistent neurological effects of HIV
infection (Gelman et al., 2013). The introduction of cART has also shifted domains of
neurocognitive impairment. Pre-cART era patients had a significantly higher percent of
impairment in tasks related to motor skills, cognitive speed, and verbal fluency, whereas,
cART era patients had a higher percent impairment in processing speed, memory, and
executive functioning (Heaton et al., 2010, Maki et al., 2015, Rubin et al., 2017). These
changes reflect a shift from subcortical and white matter disruption to cortical impairment
from pre-cART to cART eras (Cysique et al., 2004). In a 2008 review, Anthony and Bell
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(Anthony and Bell, 2008) posit that a shift in pathology has occurred from the basal
ganglia to the hippocampus, entorhinal cortex, and temporal cortex, reflecting the
neurocognitive findings of the clinical data. cART has had subtle/variable effects on
HAND partially due to variable blood brain barrier (BBB) penetrance of the ARVs used.
More effective penetrance may help dampen some aspects underlying HAND, but some
studies have found that those on cART with higher BBB penetrance have worsened
neurological impairment (Marra et al., 2009). This may be a result of direct ARV
neurotoxicity, potentially contributing to the continuation of HAND and the shift in affected
brain areas and symptomology noted. In vitro studies on ARVs have found that some
induce dendritic beading at physiologically relevant concentrations (Robertson et al.,
2012) and can prevent microglial phagocytosis of amyloid β (Aβ) (Giunta et al., 2011)
offering mechanisms by which certain ARVs may contribute to CNS pathology. Even with
effective cART, the neurotoxic HIV protein Tat can be found in the cerebrospinal fluid
(CSF) of PWH on cART and is correlated with worse performance in motor speed and
information processing (Henderson et al., 2019).
The predominant theory underlying HIV entry into the CNS, dubbed the Trojan
Horse Theory, posits that HIV crosses the BBB early after infection via infiltrating
monocytes/macrophages and, possibly T cells. Specifically, infected CD14+/CD16+
monocytes are highly vulnerable to infection and critical for viral seeding of the CNS
(Fischer-Smith et al., 2001, Ellery et al., 2007). Additionally, they have increased
transmigration across the BBB due to HIV-induced C-C chemokine receptor type 2
(CCR2) elevation and heightened sensitivity to chemokine C-C motif ligand 2 (CCL2)
(Williams et al., 2013). After entry, monocytes establish residence and produce virus
8

within the brain, which then infects susceptible CNS cells. Productive infection occurs in
perivascular macrophages and microglia. There is also strong evidence showing infection
of astrocytes (with unproductive viral replication) (Eugenin et al., 2011, Wiley et al., 1986,
Deiva et al., 2006), and neural progenitor cells (NPCs) (Balinang et al., 2017, Lawrence
et al., 2004, Schwartz et al., 2007, Skowronska et al., 2018). While microglia and
macrophages are widely accepted to actively replicate and release infective HIV, both
infected astrocytes and microglia also release neurotoxic HIV proteins. Further, even
uninfected microglia and astrocytes respond to viral insult by shifting towards a
proinflammatory phenotype. While neurons themselves are not infected, they incur
damage through viral and proinflammatory factors released by infected/activated glia
resulting in reduced axodendritic complexity, hyperexcitability, and possibly excitotoxicity.
This neuronal damage resulting in disrupted circuitry, is thought to underlie the symptoms
associated with HAND (Masliah et al., 1997).
The role of microglia and resident macrophages in HAND
Microglia are the resident immune cells of the CNS and play an integral role in
synaptic and dendritic maintenance and, thus, facilitate neuronal circuitry through
phagocytosis of cellular debris and synapses. Expression of CD4 and CCR5 begets
microglial susceptibility to R5-tropic strains of HIV-1 infection (Gelman et al., 1997,
Epstein and Gendelman, 1993). Along with perivascular macrophages and monocyte
derived macrophages microglia are the primary sites of active replication in the brain.
Viral DNA can be found in all three cell types (Wiley et al., 1986, Koenig et al., 1986) even
with effective cART (Ko et al., 2019) and are thought to be sites of viral reservoir in the
CNS (Wallet et al., 2019). At basal conditions, microglia have ramified morphology,
9

surveying synapses and extracellular matrix for debris, but microglia of the HIV-infected
brain have a reactive, ameboid morphology (Everall et al., 2009). Pre-cART era,
postmortem staining of human brain sections found increased interleukin-1 β (IL-1β) and
tumor necrosis factor (TNF) in the cerebral cortex and white matter of HIV patients
compared to controls. Microglial activation can be found even in patients receiving
effective cART (Garvey et al., 2014). In addition to increased markers of reactive
microglia/inflammation, HIV Tat-exposed microglia have reduced phagocytosis in vitro
(Giunta et al., 2008) which may contribute to the accumulation of Aβ in the brains of cART
era HIV patients, a hallmark of neurodegeneration and Alzheimer’s Disease (Green et al.,
2005).
Microglia are exposed to HIV proteins in vivo including, Tat, gp120, Vpr, and nef.
In vitro studies have examined how these factors affect microglia and their
cytokine/chemokine profile after exposure. Microglia respond to HIV-1 infection, and Tat
or gp120 exposure with a proinflammatory phenotype releasing CCL2 , CCL4, CXCL10,
interferon γ (IFNγ), C-X-C motif chemokine ligand type 8, IL-1β, TNF, CCL5, IL-6, and IL8 in vitro which contributes to neuroinflammation and neurotoxicity in the HIV-infected
brain (D'Aversa et al., 2004, Chivero et al., 2017, Jin et al., 2012, Sheng et al., 2000, ElHage et al., 2015). Several of these factors are also upregulated in in vivo models of
HAND including TNF and IL-1β (Chivero et al., 2017, Jin et al., 2012). Tat exposure can
also induce glutamate release by microglia, directly contributing to hyperexcitability
(Gupta et al., 2010). Overall, microglia are susceptible to HIV infection, serving as a
reservoir of virus in the brain. They exhibit decreased phagocytic capacity, and release
neurotoxic inflammatory mediators that are either directly neurotoxic, or that result in
10

secondary neurotoxic outcomes via the activation of astrocytes and other resident CNS
cells. They are critical drivers of the neuronal dysfunction that underlies the symptoms
associated with HAND.
The role of astrocytes in HAND
Astrocytes

perform

a

myriad

of

functions

including

phagocytosis,

cytokine/chemokine release, metabolic/trophic support to neurons, and synaptic cleft
clearance. These functions become dysregulated as a result of viral and inflammatory
insult. Some studies provided evidence that astrocytes can be infected by HIV, albeit,
unproductively (Churchill et al., 2006). While astrocytes express no detectable CD4,
evidence indicates that they can be infected by HIV in vivo (Tornatore et al., 1994, Ranki
et al., 1995, Takahashi et al., 1996, An et al., 1999, Anderson et al., 2003, Churchill et
al., 2009) and in vitro under specific conditions (Li et al., 2020). Lacking CD4, astrocytic
infection requires an alternate route of viral integration or internalization. The generally
accepted mechanism involves CD4-independent endocytosis (Chauhan et al., 2014, Hao
and Lyman, 1999). A recently published study described in detail the mechanism
underlying productive HIV infection in human fetal astrocytes (Li et al., 2020). Their
proposed mechanism involves CD4-indpendent, CXCR4-dependent endocytosis of
immature virion and escape of endolysosomal degradation to establish productive
infection. Immature virions are vital to this proposed mechanism. Maturation of the HIV
viral particle occurs soon after budding from the host cell, thus, an infected lymphocyte
must be in close proximity to the astrocyte, which corresponds with earlier proposed
mechanisms that require cell-to-cell contact (Nath et al., 1995, Li et al., 2015, Luo and
He, 2015) and post mortem studies showing that infected astrocytes are primarily found
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in close proximity to vasculature (whereby astrocytic end feet would be in close proximity
to circulating, infected lymphocytes). While difficult to quantify, evidence from studies that
combined

immunohistochemistry

for

astrocytic

and

microglial

markers,

laser

microdissection, and PCR demonstrated that as much as 19% of astrocytes contain HIV
DNA and the frequency of astrocytic infection was correlated with severity of neurological
complications (Churchill et al., 2009). There is still some dispute regarding the presence
of astrocytic infection in vivo (Ko et al., 2019), but the small sample size in this study may
suggest that astrocytic infection varies between PWH, and may be dependent on viral
strains present and lymphocyte infiltration of the CNS. These variables exemplify some
components of cellular and viral heterogeneity of HIV infection and disease progression
which likely underlie the heterogeneity of HAND.
Regardless of how much infection occurs in vivo, astrogliosis has been well
documented in postmortem tissue of HIV-1-infected subjects (Vitkovic and da Cunha,
1995, Desplats et al., 2013, Xing et al., 2009) and astrocytes show elevated release of
proinflammatory cytokines/chemokines in response to HIV proteins in vitro. HIV-1 Tat and
gp120 stimulate an inflammatory response and the release of IL1β, CCL2, IL6, TNFα,
CCL5, and CCL2 (Wesselingh et al., 1997, Nottet et al., 1995, El-Hage et al., 2009, ElHage et al., 2005, Weiss et al., 1999). Astrocytes also release stromal cell-derived factor
1 in response to IL1β released by HIV infected macrophages (Churchill et al., 2009).
Astrocytes take up extracellular Tat (Ma and Nath, 1997) and infected astrocytes can
release Tat and gp120 (Fan and He, 2016, Rahimian and He, 2016, Chauhan et al., 2003,
Toggas et al., 1994). These factors, along with those released by microglia, contribute to
neuroinflammation of the HIV-infected brain.
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Beyond their immune roles, astrocytes participate in the tripartite synapse, clearing
excess neurotransmitters and, in some cases, releasing neurotransmitters themselves to
modulate neuronal plasticity (Nedergaard, 1994, Parpura et al., 1994, Araque et al., 1998,
Wang et al., 2012a). Astrocytic excitatory amino acid transporter (EAAT) 1 and EAAT2
are the primary sources of glutamate clearance in the brain (Bergles and Jahr, 1997,
Schousboe et al., 1977, Gundersen et al., 1995). EAAT2 is decreased after exposure to
HIV proteins in vitro (Wang et al., 2003, Pappas et al., 1998) as well as in postmortem
brain tissue of HIV-1 infected subjects (Xing et al., 2009). Resultant excess glutamate is
then available to bind Ca2+ permeable channels such as N-methyl-D-aspartate receptor
(NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
contributing to aberrant neuronal activation and, thus, neuronal hyperexcitability.
The extreme metabolic demands of neuronal activity beget their reliance on
astrocytic support in the form of lactate via the astrocyte-neuronal lactate shuttle. Lactate
derived from astrocytes is released into the extracellular matrix for neurons to uptake to
allow neuronal adenosine triphosphate (ATP) generation needed for synaptic
transmission while bypassing the glycolytic pathway (Suzuki et al., 2011, Vilchez et al.,
2007). Tat induced rises in Ca2+ were found to increase mitochondrial Ca2+ uniporter Ca2+
uptake in astrocytes, resulting in decreased glycolysis and lactate transport to neurons
(Natarajaseenivasan et al., 2018). Thus, Tat-induced astrocytic misallocation of energy
substrates may deprive neurons of the metabolic support needed for proper neuronal
activity.
HIV-induced neuronal dysfunction
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In addition to HIV/HIV protein-induced, glial-mediated neuroinflammation and
neural homeostasis disruption, Tat and gp120 have direct neuronal targets. Tat has
affinity for NMDAR (Haughey et al., 2001, Prendergast et al., 2002, Chandra et al., 2005,
Self et al., 2004), and can activate AMPAR (Longordo et al., 2006, Fitting et al., 2014),
voltage-gated L-type Ca2+ channels (Napier et al., 2014), and the transient receptor
potential canonical channel (Peng et al., 2012), all of which lead to increased neuronal
[Ca2+]i. In addition to dysregulating cell membrane Ca2+ channels, Tat induces release of
Ca2+ through internal sources. Tat induction of inositol 1,4,5-triphosphate receptor and
ryanodine receptor signaling pathways leads to increased [Ca2+]i from endoplasmic
reticulum stores (Haughey et al., 1999, Perry et al., 2010). External influx and internal
release disrupts Ca2+ homeostasis leading to excessive activation, metabolic disruption,
and neuronal death in vitro (Kim et al., 2018, Nath et al., 1996, Brailou et al., 2008, Cheng
et al., 1998, Norman et al., 2007, Zou et al., 2011). gp120 targets vary depending on
tropism (CXCR4, CCR5, or dual (CXCR4- and CCR5-tropic)) and CXCR4 and CCR5 can
both be found on subpopulations of neurons. Thus, CXCR4, CCR5, and dual-tropic gp120
can also induce enhanced [Ca2+]i and neuronal death in vitro (Podhaizer et al., 2012, Kaul
et al., 2007, Xu et al., 2011). While neuronal death is not often seen in vivo, the pathways
initiated by Tat and gp120 can lead to loss of synaptodendritic complexity,
hyperexcitability, and circuitry disruption found in these models of HAND and regulate,
along with glial-mediated inflammation and metabolic disruption, neuropathology seen in
PWH.
The prevailing viewpoint on HIV-induced neuronal excitotoxicity and/or
hyperexcitability has centered around excessive glutamate and neuronal [Ca2+]i, which
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can result in a positive feedback loop, through increased [Ca2+]i stimulating glutamate
release, which, in turn, activates [Ca2+]i permeable channels; a process that is further
exacerbated by decreased astrocytic glutamate transport and increased microglial
glutamate release. While increased excitation certainly tips the scale of neuronal
excitatory-inhibitory balance, this only takes into account one side of the story. Increasing
evidence of vulnerability of GABAergic markers and function has underscored the
importance of loss of inhibition in HIV-induced excitatory-inhibitory imbalance. Human
post-mortem brain gene expression array studies found downregulation of mRNA
associated with GABAergic transmission in the neocortex and striatum of patients with
HAND correlating with neurocognitive impairment (Gelman et al., 2012a, Buzhdygan et
al., 2016). Corollaries to the changes in human gene expression have been found in DOXinducible, GFAP-driven Tat transgenic mice. Mice expressing the Tat transgene (Tat+)
showed decreased inhibitory synaptic markers in the hippocampus associated with
deficits in spatial memory compared to those lacking the Tat transgene (Tat-) mice (Fitting
et al., 2013). These results were expanded upon to demonstrate selective loss of
parvalbumin+, nitric oxide synthase+, neuropeptide Y- interneurons (Marks et al., 2016).
Additionally, Tat+ striatal GABAergic neurons, particularly dopamine receptor D2 (D2R)expressing medium spiny neurons (MSNs) displayed reduced spine density and
increased dendritic varicosities compared to their control counterparts (Fitting et al., 2010,
Schier et al., 2017). Studies have also found disrupted GABA release and reduced
amplitude and frequency of miniature induced post synaptic currents (mIPSC) from Tat
exposure (Musante et al., 2010, Xu et al., 2016). These studies provide evidence of
disinhibition through loss of GABAergic synapses and transmission after exposure to HIV
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or HIV proteins and impetus to further study loss of inhibition in relation to the HIV-induced
excitatory-inhibitory imbalance.
Opiate use and its impact on HAND progression
The United States is in the midst of an opioid epidemic with approximately 11
million people reported to have misused opioids in 2017 (SAMHSA, 2017). Opiates act
by mimicking endogenous opioid ligands, activating the µ-opioid receptor (MOR), and δopioid receptor (DOR) and κ-opioid receptor (KOR) to a lesser extent. Due to their strong
analgesic effects, opioids have been the primary source of prescription pain medication
(National Academies of Sciences and Medicine, 2017). Activation of the classic reward
pathway by opiates occurs through MOR activation and subsequent inactivation of
GABAergic neurons resulting in disinhibition of ventral tegmental area (VTA) dopamine
(DA)-ergic neurons and increased DA release in the nucleus accumbens (NAcc)
(Johnson and North, 1992) which underlies the abuse liability of opiates.
HIV infection and substance use disorders (SUD) are interlinked epidemics.
Injection drug use (IDU) contributed to 20% of recorded HIV cases in 2016 (NIDA, 2019)
and people who inject drugs are 22 times more likely to acquire HIV (UNAIDS, 2019).
Illicit drug use is not the only route through which PWH are exposed to opiates. Recent
studies found that 36% of PWH had chronic pain diagnoses and up to 50% of PWH were
prescribed opiates (Chilunda et al., 2019, Denis et al., 2019). Drug use is associated with
poor cART adherence and increased viral load in the CSF (Denis et al., 2019, Canan et
al., 2018, King et al., 2012). Clinical data has been inconsistent in establishing a clear link
between opiate use and the progression of HAND. One consistent confound being that
most drug abusers use more than one substance, limiting conclusions that can be drawn
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about the effects of opiates themselves. Despite this, some evidence has linked opiate
use to worsened neurocognitive progression and higher rates of dementia (Chiesi et al.,
1996, Bell et al., 1998, Bell et al., 2002, Lucas et al., 2006, Byrd et al., 2011). Byrd and
colleagues (Byrd et al., 2011) found an association between lifetime heroin use and poor
recall association among PWH. Post mortem studies have also found that HIV
encephalopathy indicators and markers of neuroinflammation were more prevalent in IDU
than non-IDU HIV patients (Smith et al., 2014, Bell et al., 1998). Despite confounds, much
of the literature associates higher prevalence and more rapid progression of
neurocognitive impairment in HIV+ IDU than non-IDU which is in accordance with studies
involving models of HAND and opiate exposure. Mechanisms underlying these changes
involve convergence of cellular and molecular pathways that induce activation of viral
reservoirs, enhanced cytokine and chemokine release, enhanced reductions of
synaptodendritic complexity, increased glutamate release/decreased uptake, resulting in
circuitry disruption and subsequent behavioral and cognitive deficits.
Accumulating evidence showing reward deficits in PWH (Anderson et al., 2016,
Plessis et al., 2015) suggests that the HIV-exposed CNS may have altered responses to
drugs of abuse, possibly increasing the likelihood of drug seeking behavior and relapse
in PWH. Imaging and postmortem studies have shown disrupted DAergic systems, such
as reduced DA, dopamine transporters (DAT), D2R, and DA reuptake in the striatum
(Chang et al., 2008, Wang et al., 2004, Kumar et al., 2009, Ferris et al., 2010), suggesting
that HIV targeting of DAergic systems may underlie changes in reward processing.
Several studies utilizing the DOX-inducible, GFAP-driven Tat-transgenic (Tat-transgenic)
mice have identified potential neuronal and molecular targets underlying these clinical
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effects. Tat exposure decreased DA levels (Kesby et al., 2016), impaired DAT function
(Ferris et al., 2009a), decreased stimulated DA release (Ferris et al., 2009b), and
decreased DA receptor expression in these mice (Kesby et al., 2016). Acute Tat exposure
also increased the rewarding effects of drugs of abuse measured by behavioral
assessment (Paris et al., 2014a, McLaughlin et al., 2014). Together, these studies
suggest HIV infection of the CNS may increase the risk of substance abuse by altering
the rewarding properties of drugs of abuse through impairment of DAergic circuitry.
Opiates primarily exert their effects through activation of MOR, which can be found
heterogeneously on neurons and glia. Opiates can increase HIV replication by decreasing
IFN expression (Wang et al., 2012b) and susceptibility to infection by increasing CCR5
expression (Guo et al., 2002, Li et al., 2003). Morphine, the primary metabolite of heroin,
can reduce EAAT1 and 2 in vivo, directly contributing to excess glutamate, and has an
additive effect with Tat to decrease glutamate buffering and increase microglial glutamate
release, in vitro and exacerbate reactive oxygen species (ROS) release in a MOR
dependent manner (Zou et al., 2011, Gupta et al., 2010, Turchan-Cholewo et al., 2009).
Morphine enhanced Tat effects can result in exacerbated neuronal death in vitro through
glial MOR activation (Zou et al., 2011) and may be dependent on the presence of glial
CCR5 (Kim et al., 2018). Elevated neurotoxicity due to gp120-morphine co-exposure is
dependent on gp120 tropism. Morphine significantly enhanced dual CXCR4-CCR5 tropic
(MN) gp120-induced neurotoxicity while having no effects on CCR5 (ADA) or CXCR4
(IIIB) toxicity (Podhaizer et al., 2012). Viral factors and morphine neurotoxic interactions
may be mediated by glycogen synthase kinase 3β (GSK3β) signaling (Masvekar et al.,
2014, Masvekar et al., 2015) and may be glial-mediated (Zou et al., 2011).
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Neuroinflammation in the HIV-opiate co-exposed brain may be sustained by
astrocytic-microglial crosstalk. Further, Tat and gp120-induced release of cytokines and
chemokines are synergistically increased with morphine co-exposure (El-Hage et al.,
2005, El-Hage et al., 2006, El-Hage et al., 2008). Combined inflammatory effects of
morphine and Tat emerge from convergence in elevated [Ca2+] and NFκB activation (ElHage et al., 2008). Thus, morphine and HIV-induced inflammatory astrocytic response
activates microglia to release proinflammatory factors resulting in a positive feedback loop
creating a cycle of sustained neuroinflammation and hyperexcitability (Hauser et al.,
2012).
KCC2
Preferential

vulnerability

of

inhibitory

neurotransmission

to

HIV-induced

degeneration has been studied in regard to reduction of GABAergic machinery and
synaptic markers (mRNA and protein) and frequency and amplitude of IPSCs. Other
neurological disorders are increasingly finding GABAergic disruption through collapse of
postsynaptic ionic gradients important for fast synaptic inhibition. Importantly, therapeutic
efficacy has been demonstrated in targeting the transporters responsible for this ionic
balance, such as K+- Cl- cotransporter-2 (KCC2).
Slc12a encodes 9 cation-Cl- transporters, including the central neuron specific,
KCC2 (Hebert et al., 2004). KCC2 is a 12 membrane-spanning protein that can exist as
monomers, dimers, trimers, or tetramers (Uvarov et al., 2009). Alternative splicing of the
KCC2 gene can give rise to two isoforms that differ by 40 N-terminal amino acid residues,
KCC2a and KCC2b (Uvarov et al., 2007). The longer isoform, KCC2a, is found more
prominently in the neonatal brain stem and spinal cord while KCC2b is strongly
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upregulated during development and is the predominant isoform in the adult brain (~90%
of KCC2 expression in mature cortex) (Uvarov et al., 2007, Uvarov et al., 2009). Studies
have not noted a difference in function between the isoforms. Both are central neuronspecific (Uvarov et al., 2009) due to activity of the RE1-silencing transcription factor
(REST) on the neuron restrictive silencer element upstream of the KCC2 promoter (Yeo
et al., 2009).
KCC2 is an electroneutral secondary active transporter that utilizes the K+ gradient
established by Na+-K+ adenosine 5’-triphosphate-(ATP)ase to extrude Cl-. This activity
maintains low intracellular Cl- ([Cl-]i) driving the influx of this anion via the ligand gated,
Cl- permeable GABAA and glycine receptors. Upon ligand binding, the inward rush of Clleads to hyperpolarization and inhibition of the postsynaptic neuron. KCC2 maintains low
(<10 mM) [Cl-]i in mature mammalian neurons resulting in the reversal potential of
GABAergic currents near resting membrane potential (Delpire and Staley, 2014). While
setting the stage for postsynaptic hyperpolarization and inhibition through Cl- regulation,
KCC2 has also been implicated in excitatory transmission. It has somatodendritic
localization and clusters around dendritic spines (Gulyas et al., 2001, Gauvain et al.,
2011, Chamma et al., 2013) and through its interaction with cytoskeleton-associated
protein 4.1 N KCC2 participates in stabilizing actin (Li et al., 2007) and is integral to
dendritic spine formation and stability (Fiumelli et al., 2013), and, thus, is vital for
glutamatergic plasticity. Taking into consideration its Cl- extrusion capacity to increase
GABAergic inhibition and its localization to spines, KCC2 is fundamental to the excitatoryinhibitory balance of neurons.
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KCC2 is upregulated during development, due to brain derived neurotrophic factor
(BDNF) activation of tropomyosin receptor kinase B (TrkB) on immature neurons, while a
transporter with opposing Cl- displacement, Na+-K+-2Cl- cotransporter (NKCC1), is
downregulated. This developmental shift was thought to result in the change of GABA
from an excitatory to an inhibitory neurotransmitter (Rivera et al., 1999, Ben-Ari et al.,
1989, Chudotvorova et al., 2005), although some data suggested that conditions of these
studies produced confounds that resulted in GABAergic excitation (Bregestovski and
Bernard, 2012). In particular, the metabolic changes that occur to neurons during the
slicing process for ex vivo slice electrophysiology may result in the accumulation of
neuronal Cl- (Dzhala et al., 2012), thus, confounding experiments performed in these
conditions. In vivo studies also demonstrated that application of GABAAR antagonists
(gabazine and bicuculine) increased neuronal activity in rat pups (P3 - P5), suggesting
inhibitory effects of GABAAR activation in the immature brain (Baram and Snead, 1990,
Bernard and Axelrad, 1993). Some evidence from these studies has been refuted (BenAri et al., 2012). In direct contradiction to the studies above, experiments demonstrated
that in P1 – 5 rats GABA does, in fact, excite immature neurons of the intact hippocampus
in vitro (Valeeva et al., 2013) and that, in immature slice preparations, physiological
concentrations of lactate or pyruvate do not alter the depolarizing effects of GABA,
suggesting that depolarizing GABA is not an artifact of inadequate energy supplies (Tyzio
et al., 2011). Further, blockade of NKCC1 with bumetanide in vivo during the early postnatal period suppressed sharp waves in the hippocampus (Sipila et al., 2006), and
attenuated electrographic seizures (Dzhala et al., 2005), suggesting depolarizing actions
of GABA. These inconsistencies may be resolved through a suggested dual excitatory
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and inhibitory role for GABA in the developing brain (Ben-Ari, 2014). This paradox may
be due to shunting inhibition, whereby depolarizing GABA initially increases synchronous
neuronal activation followed by reduced network activity by inhibiting depolarization
above the GABA reversal potential, decreasing glutamate receptor currents (Khalilov et
al., 1999). An attempt to finally resolve the role of GABA during development was made
by Kirmse and colleagues (Kirmse et al., 2015), in which in vivo whole-cell voltage-clamp
and 2-photon Ca2+ recordings of P3 - 5 mouse V1 neurons were made during puff
application of GABA. Their voltage-clamp findings demonstrated that GABA is
depolarizing in the majority of cells, but did not induce action potentials and, thus, lacked
direct excitatory effects. In vivo Ca2+ recording revealed that application of GABA did not
induce Ca2+ transients and that application of GABA agonist (benzodiazepine) and
antagonist (gabazine) strongly inhibited and promoted spontaneous networks,
respectively. Taken together, these data show that GABA is depolarizing, but inhibitory
at the network level (likely through shunting inhibition) in the immature CNS (Kirmse et
al., 2015). While there has been debate as to the exact postsynaptic effects of GABA in
the developing CNS, it should be noted that a shift in neuronal expression pattern from
NKCC1 dominant to KCC2 dominant has not been questioned, but rather the
physiological consequences of this phenomenon.
Membrane localization of KCC2 is largely post-translationally regulated in mature
neurons. With an average membrane turnover rate of 20 – 30 minutes (Lee et al., 2010,
Rivera et al., 2004), its trafficking, membrane stability, and degradation are tightly
regulated by several phosphorylation sites (Come et al., 2019). The KCC2 N-terminal
domain (NTD) was demonstrated to be required for membrane trafficking through a study
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involving NTD deletion and the C-terminal domain (CTD) is involved in membrane stability
and contains the majority of phosphorylation sites (Friedel et al., 2017) . Phosphorylation
of S932, T934, S937, S940 increase membrane stability while phosphorylation of T1009,
T1007, T906, Y903, Y1087, decrease its stability and activity. Proteomic studies identified
several other phosphorylation sites on KCC2, but whether they play a role in
transportation and/or stability remains unknown (Cordshagen et al., 2018, Weber et al.,
2014). Phosphorylation and consequential changes in KCC2 activity are mediated by
several upstream pathways. One well-studied pathway involves protein kinase C (PKC)
and protein phosphatase 1 (PP1)-dependent phosphorylation and dephosphorylation of
serine 940 (S940), respectively. NMDAR activation and subsequent [Ca2+]i increase leads
to a molecular pathway involving PP1 dephosphorylation of S940 and its internalization,
evidenced by KCC2 rescue via AP5 antagonism of NMDAR (Lee et al., 2011). In contrast,
PKC phosphorylation of S940 increases its membrane stability and decreases clathrininduced internalization (Lee et al., 2007). Conversely, phosphorylation of Y903 and
Y1087 result in loss of KCC2 activity via clathrin dependent internalization and lysosomal
degradation

(Lee

et

al.,

2010).

Interestingly,

both

excitatory

and

inhibitory

neurotransmission differentially regulate KCC2 membrane stability and activity.
Postsynaptic excitation by glutamate decreases KCC2 membrane stability through
NMDAR-associated mechanisms discussed above. GABA was recently shown to be an
upstream regulator of KCC2 as well. Post synaptic increase in Cl- reduced with-no-lysine
1 (WNK1) activity and subsequent phosphorylation of T1007, increasing its stability
(Heubl et al., 2017). Thus, NMDAR-mediated Ca2+-induced decrease in activity and
GABAAR-mediated Cl--induced increase provides another mechanism by which neurons
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can fine tune the balance of inhibition/excitation through KCC2 membrane stability within
localized dendritic compartments.
The link between KCC2 and neurological disorders has grown steadily over the
last two decades. Loss of KCC2 activity was first linked to models of epilepsy (Rivera et
al., 2002) and mutations in Slca12 were later found to underlie febrile seizures and
generalized epilepsy in small cohorts of humans (Puskarjov et al., 2014, Kahle et al.,
2014). KCC2 loss precedes cyclothiazide-induced epileptiform activity, suggesting that it
is the trigger setting the stage for seizures rather than a consequence of excessive
NMDAR activation in these settings (Chen et al., 2017a). Hyperexcitability is a hallmark
of many neuroinflammatory disorders. Evidence continues to accumulate linking KCC2
loss and subsequent Cl- dysregulation as a mediator of hyperexcitability in several models
of these diseases including Alzheimer’s disease (Chen et al., 2017b), traumatic brain
injury (TBI) (Lizhnyak et al., 2019), Huntington’s (Dargaei et al., 2018), Rett syndrome
(Tang et al., 2016), and neuropathic pain (Mapplebeck et al., 2019, Coull et al., 2005). A
recent publication (Pisella et al., 2019) found that mice carrying a heterozygous KCC2
mutation to reduce its Cl- extrusion capacity had ‘Autism-like’ phenotypes. Behaviors
included abnormal ultrasonic vocalizations and social deficits which correlated with
delayed GABAergic maturation.
Opiate use and dependence are well known to dysregulate both spinal and striatal
circuitry. Loss of KCC2 activity was found in lamina 1 neurons of the spinal dorsal horn
disinhibiting spinal nociceptive output, after chronic morphine exposure inducing
hyperalgesia (Ferrini et al., 2013, Ferrini et al., 2017). In contrast to immature neurons,
TrkB activation downregulates KCC2 in mature neurons, which was shown to be the
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mechanism here. Pharmacological maintenance of KCC2 was demonstrated to restore
morphine’s analgesic effects in rats (Ferrini et al., 2017). During the development of
morphine dependency, GABA switched from an inhibitory to excitatory signal in rats
(Laviolette et al., 2004, Vargas-Perez et al., 2009). While not explicitly linked to KCC2,
Cl- dysregulation is a likely mechanism underlying this switch and, thus, KCC2 is also
likely dysregulated.
Due to the increasing reports of KCC2 dysregulation in neurological diseases,
Gagnon et al. (Gagnon et al., 2013) sought to design a compound that could maintain
KCC2 activity. Through development of a novel KCC2 activity assay, they isolated
CLP257, an arylmethylidine compound that restored Cl- extrusion in neurons treated with
BDNF to reduce KCC2 activity and rescued KCC2 membrane expression. To enable in
vivo study of pharmacological reintroduction of Cl- extrusion, a prodrug of CLP257,
CLP290, was designed. CLP290 has a half-life of 5 h and is non-toxic with a maximum
daily dose of 2,000 mg in rats (Gagnon et al., 2013). It was administered twice a day at
100 mg/kg to rats to reverse morphine-induced hyperalgesia (Ferrini et al., 2017) and at
50 mg/kg once a day to restore membrane expression and rescue rotarod performance
after TBI (Lizhnyak et al., 2019). In mice, daily 35 mg/kg intraperitoneal injections of
CLP290 restored stepping ability in spinal cord injured mice by restoring spinal cord
inhibitory interneuron circuitry (Chen et al., 2018) and daily injections of 100 mg/kg to
amyloid precursor protein knockouts rescued hippocampal inhibitory post synaptic
current amplitude (Chen et al., 2017b).
KCC2 activity and turnover is tightly regulated through the activity of REST, TrkB,
kinase, and phosphatase activity mediated by numerous upstream pathways that play
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important physiological roles in healthy CNS development and activity. These events
include a developmental GABAergic switch, maintaining low [Cl-]i for postsynaptic
hyperpolarization/inhibition, and maintenance of excitatory synapses and glutamatergic
plasticity. These events can become dysregulated and contribute to hyperexcitability and
circuit dysregulation under pathological conditions.
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Chapter 2
In vitro primary human CNS models
(This chapter was, in part, accepted for publication in Neurobiology of Disease, article in
press)

Introduction
In vitro models allow for the study of precise cellular and molecular pathways with
control that may not be attainable using in vivo models. Rodent in vitro models have been
instrumental in unravelling the mechanistic pathophysiology of many CNS disorders.
Although, inherent drawbacks arise in the attempt to model human-specific diseases such
as Alzheimer’s Disease, Parkinson’s Disease, and HIV-associated neurocognitive
disorders (HAND) in nonhuman cells. Human induced pluripotent stem cells (hiPSCs)
were first generated from reprogrammed human somatic skin cells (Takahashi et al.,
2007, Yu et al., 2007). hiPSCs have since advanced to the point of induction and
differentiation of physiologically active human neurons with the capability of driving
neuronal subset differentiation. These induced neurons (iNeurons) are critical to model
human-specific CNS diseases. As with any model, there are inherent weaknesses found
in iNeurons, including lost cytoarchitecture, reduced intercellular interactions, and artificial
differentiation/development among others. Thus, for every study one must determine
which model(s) can provide the most effective route towards answering the question athand and must take into consideration the inherent strengths and weaknesses of each.
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To attempt to restore aspects of cytoarchitecture and cellular diversity found in vivo
while retaining the control provided by in vitro models, 3-dimensional (3D) organoid
models have grown in favor. One early CNS organoid system, human brain aggregates
(BrAgg), described by Pulliam and colleagues contain the major cellular subsets of the
CNS in proportions similar to the human brain (40% neurons, 40% astrocytes, 15%
oligodendrocytes, 5% microglia) (Pulliam et al., 1988, Pulliam et al., 1991, Pulliam et al.,
1998). Recent advances have shown the promise of such brain organoid development.
Long-term culturing of hiPSC-derived organoids show major characteristics of the
developing cortex including apical-basal polarity, interkinetic nuclear migration, neuronal
migration and six cortical layers and brain region-specific organoids (Qian et al., 2018,
Qian et al., 2016).
Here, we sought to develop and characterize translationally relevant primary
human CNS models. We developed a differentiation protocol for a novel primary mixed
astrocyte-neuron culture model (hNeuron) and further characterized BrAgg, initially
described by Pulliam et al. (Pulliam et al., 1988) and demonstrate their utility as a model
for HAND. The use of primary cells derived from human fetal CNS tissue, maintains
natural cellular development until the point of pregnancy termination and BrAgg maintains
critical intercellular interactions and provides stability for long-term culture experiments.
Materials and Methods
Primary hNPC dissociated culture.
Human neural progenitor cells (hNPCs) were derived from human CNS tissue at
15 - 17 weeks gestation (Advanced Biosciences Resources; Alameda, CA). Tissue was
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passed through 120 µM mesh, centrifuged and washed with rinse media (DMEM
supplemented with 1.5% glucose, 1% amphotericin B (Thermo Fisher), 50 ng/mL
gentamycin, and 1% Pen/Strep) twice, and dissociated cells were plated on poly-L-lysine
(10 µg/mL) and laminin (2 µg/mL) coated flasks. hNPCs were maintained in NPC media:
DMEM F12 supplemented with 0.6% glucose, 10% B27 (without Vit A; Thermo Fisher
Scientific), 20 ng/mL fibroblast growth factor (FGF; R&D Systems, Minneapolis MN), 20
ng/mL Epidermal growth factor (EGF; EMD Millipore, Billerica, MA), 10 ng/mL leukemia
inhibitory factor (LIF; EMD Millipore, Billerica, MA), 1% Pen/Strep, 5 mM HEPES (N-2hydroxyethylpiperazine-N-3-ethane sulfonic acid; Thermo Fisher Scientific) with media
changed every 3 or 4 days.
Dissociated neuronal differentiation.
Upon 80 - 90% confluency, hNPCs were detached using Accutase cell detachment
solution (Millipore) and plated on poly-L-lysine (50 µg/mL) and laminin (100 µg/mL)
coated 12-mm-diameter coverslips (immunostaining) or glass bottomed MatTek dishes
(functional imaging) at 12,000 - 15,000 cells/coverslip in DMEM-F12 medium
supplemented with 0.6% glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific),
1% Pen/Strep, 5 mM HEPES (Thermo Fisher Scientific), and 10 ng/mL brain derived
neurotrophic factor (BDNF; Sigma). After 7 DIV, medium was exchanged gradually (50%
on days 7 and 9) and then fully (100% every 72 - 96 h) to BrainPhysTM (STEMCELL
Technologies Inc, Vancouver, BC, CAN) supplemented with SM1 (STEMCELL
Technologies Inc).
BrAgg culture.
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BrAgg cultures were initiated and maintained using protocols established by
Pulliam et al (Pulliam et al., 1988). Briefly, 15 – 17 wk human fetal CNS tissue (Advanced
Biosciences Resources; Alameda CA) was passed through 120 µM mesh, centrifuged,
and washed twice with rinse media. Cells were then transferred to SigmacoteTM (Sigma)
coated 25 mL DeLong flasks at 30 million cells per flask containing 5 mL growth media
(DMEM supplemented with 0.75% glucose, 50 ng/mL gentamycin (Thermo Fisher), 10%
fetal bovine serum (FBS), and 1% Pen/Strep). After 48 h, BrAgg were transferred to
sigmacote-coated 50 mL DeLong flasks containing 10 mL exchange media (DMEM with
0.75% glucose, 50ng/mL gentamycin, 15% FBS, and 1% Pen/Strep). BrAgg were
maintained rotating at 80 RPM in 10% CO2 and 37° C with 50% media change (exchange
media) every 48 h.
HIV-1 propagation and HIVsup preparation.
HIV-1BaL was propagated using methods previously established (Balinang et al.,
2017). Briefly, isolated peripheral blood mononuclear cells (PBMCs) from peripheral
blood Leuko Paks (ZenBio, Research Triangle Park, NC) were activated with 1 mg/mL
phytohemagglutinin (PHA) for 48 h, then infected with HIV-1BaL (NIH AIDS Reagent
Program) at 1 ng/mL [p24]. After 72 h, infection was assayed using p24 antigen ELISA
kit (Advanced Bioscience, Rockville, MD) and supernatant harvested and frozen at −80°
C for HIVsup experiments. HIVsup used in all BrAgg experiments was from the same source
sample to reduce variability.
Immunocytochemistry.
hNeuron were fixed with 4% paraformaldehyde for 15 min after 21 DIV. Coverslips
were then permeablilized with 0.1% Triton-X 100 in 0.1% BSA and blocked for 1 h at room
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temperature in 0.1% BSA and 1% goat serum. Cellular markers were detected by
incubating for 1 h with antibodies specific for microtubule-associated protein 2 (MAP2)
(1:500; Millipore, Burlington, MA), glial fibrillary acidic protein (GFAP; 1:1000; Millipore),
GAD67 (1:500; Abcam), glutaminase (1:500, Abcam), tyrosine hydroxylase (TH; 1:1000;
Abcam), MOR (1:500; Antibodies Incorporated; Davis, CA), KCC2 (1:1000, Protein Tech),
or NKCC1 (1:100; Abcam). AlexaFluor 488 and 594-conjugated secondary antibodies
(1:1000, Thermo Fisher) were used and Hoechst 33342 (1:10000; Invitrogen) detected
nuclei.
BrAgg were fixed with 4% paraformaldehyde for 30 min, permeabilized for 30 min,
and blocked for 1 h. BrAgg were incubated overnight with antibodies specific for MAP2,
GFAP, Iba-1 (1:1000; Wako ), GAD67, and 2’3’-cyclic-nucleotide 3’-phosphodiesterase
(CNPase; 1:500; Abcam) to determine cellular subsets present. AlexaFluor 488 and 594conjugatged secondary antibodies and Hoeschst33342 were used.
Both hNeuron and BrAgg were visualized and images obtained with Zeiss LSM
700 confocal module configured to an Axio Observer Z.1 and Zen 2010 software (Zeiss
Inc.).
BrAgg infection with HIV-1Ba-L.
To determine infectivity of BrAgg, we incubated cultures with varying
concentrations of purified HIV-1Ba-L or HIV-1Ba-L-infected PBMC supernatant (HIVsup)
during culture initiation. BrAgg supernatants were collected and frozen with HALTTM
Protease & Phosphatase inhibitor Cocktail (Thermo Fisher) to prevent protein
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degradation at -80º C every 48 h. HIV-1 concentrations were then estimated using p24
antigen ELISA kit (Advanced Bioscience, Rockville, MD).
HIVsup Preparation.
HIV-1BaL was propagated using methods previously established (Balinang et al.,
2017). Briefly, isolated PBMCs from peripheral blood Leuko Paks (ZenBio, Research
Triangle Park, NC) were activated with 1 mg/mL PHA for 48 h, then infected with HIV1BaL (NIH AIDS Reagent Program) at 1 ng/mL p24. After 72 h, infection was assayed
using p24 antigen ELISA kit (Advanced Bioscience, Rockville, MD) and supernatant
harvested and frozen at −80° C for HIVsup experiments. HIVsup used in all experiments
was from the same source sample to reduce variability.
Statistics.
Changes in BrAgg [p24] within subjects (across days) were assessed by repeatedmeasures analysis of variance (ANOVA) in R. Bonferroni post hoc analysis corrected for
multiple comparisons after comparisons of simple main effects. Effects were considered
significant when p < 0.05.
Results
hNPC differentiation and hNeuron characterization.
We developed a protocol to differentiate hNPCs into mature hNeurons. EGF, FGF,
and LIF initially maintain hNPC pluripotency. These factors were replaced with BDNF to
promote neuronal survival and differentiation for seven days. Next, cells were gradually
transitioned to BrainPhys medium, which more accurately mimics in vivo physiological
conditions, increases spontaneous and evoked action potentials, and increases
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frequency and amplitude of spontaneous and induced inhibitory post synaptic potentials
(IPSCs) compared to classic basal media (Bardy et al., 2015). After a total of 3 weeks in
vitro, 53 ± 3.3% of cells are MAP2+/ GFAP- neurons and 44 ± 3.5% GFAP+ astrocytes
(Fig. 2.1). Neurons were found to be primarily glutaminase+ (~75%), and glutamate
decarboxylase+ (~25%), with few tyrosine hydroxylase+ (~1%) neurons (Fig. 2.2). Both
neurons and glia present in these cultures were found to express MOR (Fig. 2.2). NKCC1
is expressed on immature neurons and opposes KCC2 activity by increasing neuronal
[Cl−]i. Its expression decreased to undetectable levels by 21 days in vitro (DIV), while
KCC2 expression increased, as expected from studies on neuronal maturation (Schulte
et al., 2018) (Fig. 2.1). These characteristics suggested that hNeurons had matured
enough to hyperpolarize in response to GABAAR activation, as evident in experiments
performed in Chapter 3.
BrAgg characterization.
BrAgg were fixed and stained for cellular markers from five to 29 DIV. We detected
the presence of astrocytes (GFAP+), neurons (MAP2+/GFAP-), oligodendrocytes
(CNPase+), and microglia (Iba1+) (Fig. 2.2). Neurons and astrocytes were present by 5
DIV and make up a majority of the cellular subsets (~40% each) (Fig. 2.2).
Oligodendrocytes and microglia make up the majority of the remaining cells present.
Oligodendrocytes were detected at 21 DIV. Microglia were detected at 5 DIV (the earliest
time point at which BrAgg were fixed and immunostained), but have distinct lineage from
NPC derived neurons, astrocytes, and oligodendrocytes, appear in the human CNS by 5
gestational weeks and, thus, are present in BrAgg from culture initiation (Bertrand et al.,
2005, Rezaie and Male, 1999). All microglia imaged have amoeboid morphology
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suggesting a proinflammatory phenotype. The neurons present appear to be GABAergic,
evidenced by detection of GAD67 on the majority of neurons visualized (Fig 2.2).
HIV-1Ba-L infection of BrAgg.
We sought to develop a model of HAND that more accurately mimics the
cytodiversity and chronic infective and inflammatory environment of the HIV-infected brain
while retaining the high levels of control and manipulation afforded by in vitro models. HIV
is capable of infecting microglia and astrocytes, thus, we wanted to create a model
reflecting this aspect of the disease. In order to achieve this goal, we determined if we
could gain active HIV-1Ba-L infection of BrAgg. Challenges inherent to this process include
determining the ideal paradigm (pure HIV-1Ba-L vs. HIVsup, concentration) to infect BrAgg
and washing out potentially new infective virus with each media change. We exposed
BrAgg to 0.5 – 2.5 ng of purified HIV-1BA-L or HIVsup (added to achieve a final concentration
of 1 ng/mL [p24]). To tackle the issue of ‘lost’ virus at each media change (50% change
every 48 h), we calculated the levels at which [p24] would be expected given day 1
concentrations and simply divided by two for each consecutive media change ([p24exp])
and subsequently subtracted that from the observed [p24] of each sample ([p24obs]) . For
example, if [p24] on Day 1 was 10 pg/mL, then by Day 9 (after media changes on days
1, 3, 5, and 7) [p24exp] = 0.625 pg/mL. Thus, the adjusted [p24] ([p24adj]) = [p24obs] –
[p24exp]. The resultant figure (Fig 2.4) displays this [p24adj] value. This is not an ideal
model of infectivity, given the activity of proteases etc. that would further decrease p24
concentrations, but quantifying these data in this way does allow for the quantification of
‘new’ [p24], and, therefore, better represents the infectivity of BrAgg. Analysis with
repeated measures ANOVA revealed a significant increase in [p24adj] within groups
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exposed to 1.25 ng HIV-1Ba-L on days 9 and 21 compared to day 1 (p < 0.05; n = 4; Fig
2.4), suggesting active infection of BrAgg by HIV-1Ba-L.
Discussion
The studies outlined here describe primary human CNS models involving the
differentiation of human gestational CNS derived hNPCs. We demonstrated that hNeuron
increase immunoreactivity for KCC2 while decreasing NKCC1 expression throughout our
novel differentiation protocol. These features allow for the mechanistic study of human
neuronal and GABAergic maturation and should be explored in future studies. hNeurons
also show promise for the study of human specific disorders in which either of these
proteins may become dysregulated resulting in disrupted GABAergic inhibition. We also
characterized BrAgg and found that all major cellular subsets of the CNS are present and
demonstrate its utility as a novel model for HAND in which there was active HIV-1 infection
of CNS cells.
Drawbacks are inherent to all models of neurodegenerative disorders and the
models described here are not immune to certain pitfalls. Tissue samples acquired for
these studies are tested for HIV infection prior to shipment, but not all potential confounds
can be controlled for. We cannot determine reasons for pregnancy termination (whether
medical necessity or otherwise), control for exogenous substance exposure (drugs of
abuse and others), or obtain maternal or paternal genetic information. We also did not
control for potential genetic abnormalities, nor did we determine if the tissue had been
exposed to other viruses. Early gestational tissue may also be difficult to acquire
depending on the everchanging legal landscape surrounding legal access to legitimate
centers for termination procedures. Once acquired, this is less of a concern for the
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dissociated cultures, for which, tissue from one source can be proliferated as hNPCs,
frozen, and used for several passages, allowing for each sample to be used in several
experiments. Due to the sheer number of cells necessary for one flask of BrAgg (30 million
cells), it is not feasible to expand and freeze hNPC for use as BrAgg. Rather, for each
BrAgg culture initiation, a separate sample source is required. The BrAgg studies here
are limited by sample size. This particularly affects studies with higher variability, such as
our assessment of infectivity, limiting conclusions from these results. A higher sample
size may have resulted in significant changes in [p24adj] at levels other than 1.25 ng HIV1Ba-L.
In this chapter, we described a novel primary human mixed astrocyte-neuron
culture model containing both GABAergic and glutamatergic neuronal subsets with
matured Cl- transporter expression. This dissociated model is particularly useful to
elucidate mechanisms underlying neuronal disruption for human specific disorders. We
also characterized BrAgg organoids which maintain components of the cyto-diversity and
proportionality of cell types of the intact human CNS. Both show promise as translationally
relevant in vitro models of human-specific neurological disorders.
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Figure 2.1. Differentiation and characterization of hNeuron. hNPCs differentiate to
~55% MAP2+/GFAP- (green) and 40% GFAP (red)+ by 14 DIV (A). Representative
images from hNeuron cultures showing immunofluorescence of MAP2 and GFAP after
21 DIV (B). hNeurons lose NKCC1 (C) and gain KCC2 (D) immunoreactivity by 21
DIV.
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Figure 2.2. Extended hNPC Differentiation. Following our neuronal differentiation
protocol, cells lose NKCC1 expression and gain KCC2 expression by 21 DIV (A). After
21 DIV, immunoreactivity for glutaminase and GAD67 demonstrate both excitatory
and inhibitory neuronal subsets were present, respectively (B). hNeuron express MOR
(C). Scale bars = 50 µM.
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Figure 2.3. BrAgg characterization. BrAgg contain neurons and astrocytes by 5 DIV,
indicated by positive staining for MAP2 and GFAP, respectively (A). Most neurons
present appear to be GABAergic due to high colocalization between MAP2+ and
GAD67+ cells (B). A minority of cells are also CNPase+ or Iba1+ indicating the
presence of oligodendrocytes and microglia, respectively (C, D). BrAgg can vary in
size from ~150 – 400 µM in diameter (A, E). Scale bars = 50 µM.
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Figure 2.4 Infection of BrAgg with HIV-1Ba-L. Exposure to 1.25 ng/mL [p24] purified
HIV-1Ba-L (blue) results in a significant increase in [p24] adjusted for initial [p24] and
media changes on days 9 and 21 compared to day 1 (*; p < 0.05; n = 4) ([p24adj]). No
significant differences were found at other exposure concentrations nor exposure to
HIVsup.
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Chapter 3
HIV and opiates dysregulate K+-Cl- cotransporter 2 (KCC2) to cause GABAergic
dysfunction in primary human neurons and Tat-transgenic mice
(This chapter was accepted for publication in Neurobiology of Disease, article in press)

Abstract
Approximately half of people infected with HIV (PWH) exhibit HIV-associated
neuropathology (neuroHIV), even when receiving combined antiretroviral therapy. Opiate
use is widespread in PWH and exacerbates neuroHIV. While neurons themselves are not
infected, they incur sublethal damage and GABAergic disruption is selectively vulnerable
to viral and inflammatory factors released by infected/affected glia. Here, we demonstrate
diminished K+-Cl− cotransporter 2 (KCC2) levels in primary human neurons after
exposure to HIV-1 or HIV-1 proteins ± morphine, resulting in disruption of GABAARmediated hyperpolarization/inhibition. We found that the HIV proteins Tat (acting through
NMDA receptors), and R5-tropic gp120 (acting via CCR5), and morphine (acting through
µ-opioid receptors) induce KCC2 loss. We demonstrate that modifying KCC2 levels or
function, or antagonizing NMDAR, CCR5 or MOR rescues KCC2 and GABAAR-mediated
hyperpolarization/inhibition in HIV, Tat, or gp120 ± morphine-exposed neurons. Using an
inducible, Tat-transgenic mouse neuroHIV model, we found that chronic exposure to Tat
also reduces KCC2. Our results identify KCC2 as a novel therapeutic target for
ameliorating the pathobiology of neuroHIV, especially PWH exposed to opiates.
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Introduction
Close to 38 million people worldwide are infected with HIV, with 50,000 new
diagnoses of HIV-1 infection per year in the US alone (UNAIDS, 2019). Up to 50% of
those infected with HIV-1 have CNS complications including HIV-associated
neurocognitive disorders (HAND) (Antinori et al., 2007, Heaton et al., 2010). It is widely
accepted that neurons are not infected by HIV-1. Neurological deficits in patients
receiving combined antiretroviral therapy (cART) are likely due to sublethal neuronal
stress and injury induced by viral proteins released from infected cells and persistent
neuroinflammation, resulting in hyperexcitability (Anthony et al., 2005, Everall et al., 2009,
Nath and Steiner, 2014, Neuenburg et al., 2002). Exposure to HIV-1 transactivator of
transcription (Tat) depolarizes neurons and leads to electrophysiological dysfunction and
hyperexcitability, partly through interactions with N-methyl-D-aspartic acid (NMDA) and
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Philippon et
al., 1994, Krogh et al., 2014). Another HIV-1 protein, gp120, binds co-receptors C-C
chemokine receptor type 5 (CCR5) and/or C-X-C chemokine receptor type 4 (CXCR4)
(Wang et al., 2003) (Kaul et al., 2007), leading to neurotoxic glial and inflammatory effects,
as well as direct neurotoxicity. Opiate use is often comorbid with HIV-1 infection and has
been implicated in increased severity of HAND (Byrd et al., 2011, Carrico, 2011, Bell et
al., 2006, Smith et al., 2014). This comorbidity is highlighted by recent HIV-1 outbreaks
in communities experiencing a surge in opiate abuse (Conrad C, 2015). In vivo and in
vitro models of HAND demonstrate that morphine, the primary bioactive metabolite of
heroin in the CNS, exacerbates HIV-1-induced neuropathogenesis primarily through the
activation of the µ-opioid receptor (MOR) on glia, and subsequent modulation of
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neuroinflammation and reduced glutamate buffering (Rodriguez et al., 2017, Bokhari et
al., 2009, Zou et al., 2011).
GABAergic neurons seem to be selectively vulnerable to damage by Tat and HIV1 infection in mouse models and post-mortem brain tissue from HIV-infected patients,
highlighting disinhibition as a potential mechanism underlying hyperexcitability in the HIVinfected brain (Marks et al., 2016, Fitting et al., 2013, Buzhdygan et al., 2016, Gelman et
al., 2012a). The deficits appear to result from a loss of GABAergic markers (including
GAD1, GAD2, and GJD2) rather than the death of GABAergic interneurons in autopsy
samples from PWH (Buzhdygan et al., 2016). Importantly, deficits in GABAergic markers
differed significantly among brain regions and linked to worse cognitive performance, but
these markers were unaffected by a history of drug abuse and differed minimally when
comparing pre- and post-cART autopsy samples (Buzhdygan et al., 2016).
KCC2 extrudes Cl− to maintain a low intracellular Cl− concentration ([Cl−]i) in
mature neurons (Blaesse et al., 2009). GABAA and glycine receptor-induced fast synaptic
inhibition is predicated on the maintenance of low neuronal [Cl−]i provided by KCC2
activity. While upregulation and subsequent increases in KCC2 activity have been
extensively studied in development, loss of KCC2 activity and/or expression have more
recently been noted in a number of neurological disorders including epilepsy (Kahle et
al., 2014, Puskarjov et al., 2014, Silayeva et al., 2015), traumatic brain injury (Lizhnyak
et al., 2019), schizophrenia (Hyde et al., 2011, Tao et al., 2012, Arion and Lewis, 2011),
Rett syndrome (Tang et al., 2016), Huntington’s disease (Dargaei et al., 2018), and
morphine-induced hyperalgesia (Ferrini et al., 2013, Ferrini et al., 2017). The KCC2
activity enhancer, CLP257, and its prodrug, CLP290, have allowed manipulation of KCC2
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activity and rescued deficits in KCC2-deficient states (Gagnon et al., 2013). While models
of HAND have been shown to disrupt GABAergic functioning, loss of KCC2 activity has
not yet been implicated in these deficits.
In addition to working with individual HIV-1 proteins, we exposed primary human
neurons (hNeurons), derived and matured from neural progenitors (hNPC), to
supernatant from HIV-1 infected monocytes (HIVsup). This supernatant reflects the
complexity of an infective milieu in that it contains multiple inflammatory/reactive factors
and virions, as well as viral proteins. The genetically encoded voltage (GEVI) and Ca2+
indicators (GECI), Archon1 (Piatkevich et al., 2018) and GCaMP6f (Chen et al., 2013),
respectively, were used to examine the functional outcomes of interactions between an
HIV+ environment and morphine on hNeurons. Specifically, we used Archon1 and
GCaMP6f to examine changes in GABAAR-mediated hyperpolarization and inhibition,
respectively. Importantly, this optical approach permitted us to manipulate and test
functional outcomes absent the biohazards inherent with invasive electrophysiological
measurements in the presence of infective HIV. Assessment of electrophysiological
activity by Archon1 is equivalent to patch-clamp recording of neuronal spiking and
subthreshold millivolt scale activity (Piatkevich et al., 2018). We demonstrate that HIVsup
and morphine target KCC2 in hNeurons, resulting in loss of GABAAR mediated
hyperpolarization (measured by Archon1) and inhibition (measured by GCaMP6f). This
suggests that dysregulation of KCC2 may play a role in circuit hyperexcitability in the HIVinfected brain. Further, we identify Tat, acting via an NMDA receptor (NMDAR)-mediated
mechanism, and gp120ADA, acting via a novel, CCR5-mediated mechanism, as viral
proteins that can dysregulate KCC2 and GABAAR-mediated inhibition. We also examined
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the effects of Tat exposure on KCC2 in an in vivo model of HAND and found significantly
diminished KCC2 in the striatum of these animals. Our results suggest KCC2 and its
upstream regulators as promising therapeutic targets to alleviate the symptoms of HAND
± comorbid opiate use.
Materials and Methods
Primary hNPC culture.
Human neural progenitor cells (hNPCs) were derived from human CNS tissue at
15 - 17 weeks gestation (Advanced Biosciences Resources; Alameda, CA). Tissue was
passed through 120 µM mesh, centrifuged and washed with medium twice, and
dissociated cells were plated on poly-L-lysine (10 µg/mL) and laminin (2 µg/mL) coated
flasks. hNPCs were maintained in NPC medium: DMEM F12 supplemented with 0.6%
glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific), 20 ng/mL fibroblast
growth factor (FGF; R&D Systems, Minneapolis, MN), 20 ng/mL epidermal growth factor
(EGF; EMD Millipore, Billerica, MA), 10 ng/mL leukemia inhibitory factor (LIF; EMD
Millipore, Billerica, MA), 1% Pen/Strep, 5 mM HEPES (N-2-hydroxyethylpiperazine-N-3ethane sulfonic acid; Thermo Fisher Scientific) with medium changed every 3 - 4 days.
Neuronal Differentiation.
Upon 80 - 90% confluency, hNPCs were detached using Accutase cell detachment
solution (Millipore) and plated on poly-L-lysine (50 µg/mL) and laminin (100 µg/mL)
coated 12-mm-diameter coverslips (immunostaining) or glass bottomed MatTek dishes
(functional imaging) at 12,000 - 15,000 cells/coverslip in DMEM-F12 medium
supplemented with 0.6% glucose, 10% B27 (without vitamin A; Thermo Fisher Scientific),
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1% Pen/Strep, 5 mM HEPES (Thermo Fisher Scientific), and 10 ng/mL brain derived
neurotrophic factor (BDNF; Sigma). After 7 DIV, medium was exchanged gradually (50%
on days 7 and 9) and then fully (100% every 72 - 96 h) to BrainPhysTM (STEMCELL
Technologies Inc, Vancouver, BC, CAN) supplemented with SM1 (STEMCELL).
HIV-1 propagation and HIVsup preparation.
HIV-1BaL was propagated using methods previously established (Balinang et al.,
2017). Briefly, isolated PBMCs from peripheral blood Leuko Paks (ZenBio, Research
Triangle Park, NC) were activated with 1 mg/mL phytohemagglutinin (PHA) for 48 h, then
infected with HIV-1BaL (NIH AIDS Reagent Program) at 1 ng/mL p24. After 72 h, infection
was assayed using p24 antigen ELISA kit (Advanced Bioscience, Rockville, MD) and
supernatant harvested and frozen at −80° C for HIVsup experiments. HIVsup used in all
experiments was from the same source sample to reduce variability.
Treatments.
hNeuron cultures were treated with HIVsup at 125 - 500 pg/mL [p24] or HIV protein
(10 - 100 nM HIV-1 Tat1-86 IIIB (clade B) or 250 pM - 1 nM R5-tropic gp120ADA, X4-tropic
gp120IIIB, or dual-tropic gp120 MN; ImmunoDx, Woburn MA) ± 500 nM morphine sulfate
for 6 or 24 h. Drug treatments: 10 µM CLP257 (Sigma), 50 µM AP5 (Alomone Labs,
Jerusalem IL), 50 nM maraviroc (MVC; BOC Sciences, Shirley, NY) were applied 30 min
prior to HIVsup, HIV protein, and morphine for 24 h experiments. 50 µM VU02440551
(Tocris, Bristol UK) was applied 2 h prior to GEVI/GECI imaging experiments.
Supernatant from uninfected but activated monocytes (UNF) was used as a control for
HIVsup. Vehicle controls were used for all other treatments.
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Immunocytochemistry and Cell Counting.
Neuronal cultures were fixed for 15 min (4% paraformaldehyde), permeabilized for
15 min (0.1% Triton-X 100, 0.1% BSA) and blocked for 1 h at room temperature (0.1%
BSA, 1% goat serum in PBS). Coverslips were then immunostained with rabbit anti-KCC2
(1:1000; Protein Tech, Rosemont, IL) and mouse anti-microtubule-associated protein
(MAP2) (1:500; Millipore, Burlington, MA) for KCC2 immunoreactivity studies Alexa Fluor
488 and 594-conjugated secondary antibodies (1:1000; Thermo Fisher, Waltham, MA)
were used for all studies as well as Hoechst 33342 (1:10000; Invitrogen, Carlsbad, CA)
to detect nuclei. Cells were visualized and images obtained using a Zeiss LSM 700
confocal module configured to an Axio Observer Z.1 and Zen 2010 software (Zeiss Inc.,
Thornwood, NY). Cells were manually counted using the CellCounter plugin for Image J.
At least 200 Hoechst+ cells were counted per sample.
GEVI/GECI Expression.
AAV serotype 1 containing GCaMP6f and Archon1 were acquired from AddGene
(plasmid # 100837; Watertown, MA) and Vector Biolabs (Malvern, PA), respectively.
hNeurons

were

treated

with

AAV1.hSyn.GCaMP6f.WPRE.SV40

or

AAV1.hSyn.Archon1.WPRE.SV40 for 5 - 7 days prior to experiments. Human synapsin
promoter (hSyn) was used to ensure neuronal specificity.
GEVI/GECI Imaging and Analysis.
Archon1 and GCaMP6f recordings were acquired at 2 or 1 KHz, respectively, with
a Neuro-CCD camera (RedShirt Imaging, Decatur, GA) mounted on a Zeiss Axio
Observer with 40× oil immersion objective. Archon1 and GCaMP6f illumination was
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achieved with an LED (UHP-T-LED; Prizmatix, Holon, IL) 640 nm excitation, 660LP
emission for Archon1 (custom-made filter cube; Omega Optical, Brattleboro, VT) and
470/40 nm excitation, 495 dichroic, 525/50 nm emission for GCaMP6f (filter set 38; Zeiss).
All recordings were performed in BrainPhys solution (STEMCELL) with 2 µM CGP55845
(GABABR antagonist; Abcam) or 2 µM CGP55845 and 100 µM picrotoxin (PTX) (GABAA
and glycine receptor antagonist; Tocris) to validate Archon1 results (Fig. S3).
Soma ROI were used for all experiments. Archon1 and GCaMP6f traces were
analyzed with a custom code in R. Both Archon1 and GCaMP6f traces were 5-point
Savitzky-Golay smoothed and GCaMP6f traces were Loess subtracted, to remove slower
transients. Fluorescence changes were calculated as ΔF/F = (FA - Fbl)/Fbl, where FA is the
fluorescence level during perfusion and Fbl is the average baseline fluorescence intensity
2.5 s prior to perfusion. Significant Ca2+ transients were counted when the trace increased
by more than four-fold of the standard deviation (SD) of background activity (measured
2.5 s prior to perfusion) and returned to baseline levels (defined as within 0.5 × SD of
mean activity).
Animals.
Male, doxycycline (DOX)-inducible, GFAP driven HIV-1 Tat-transgenic mice (10 –
12 weeks old) were used to explore the effects of Tat expression on KCC2. Mice
expressing the tat and rtTA transgenes (Tat+) or mice lacking the tat transgene, but
expressing the rtTA transgene (Tat−), were fed doxycycline-containing chow (6 mg/g,
Harlan Indianapolis, IN) for 2 weeks prior to sacrifice. Animal procedures were approved
by the Virginia Commonwealth University Institutional Animal Care and Use Committee
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and are in accordance with Association for Assessment and Accreditation of Laboratory
Animal Care guidelines.
Immunoblot.
KCC2 presence was examined by immunoblotting striatal tissue from Tat+ and
Tat- mice. Striata were freshly harvested and homogenized in RIPA lysis buffer (Sigma)
and HaltTM Protease & Phosphatase Inhibitor Cocktail (Thermo Fisher). Lysates were
then centrifuged and stored at -80º C. Protein concentration was measured using BCA
protein assay (Pierce, Rockford, IL). 40 µg of lysates were loaded per well onto 4 – 20%
Tris-HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred to
PVDF membranes (Bio-Rad) and probed with antibodies against KCC2 (1:2000; Protein
Tech) and GAPDH (1:2000; Abcam). Alexa Fluor 647 and 488-conjugated secondary
antibodies (1:2000; Thermo Fisher) were used to detect proteins. A Bio-Rad ChemiDocTM
MP Imaging System and Image Lab were used to measure and analyze protein levels,
respectively.
Statistics.
KCC2 immunocytochemistry studies were assessed using three or two-way
analysis of variance (ANOVA; R) to determine the effects of Tat1-86/gp120/HIVsup,
CLP257/AP5/MVC, and morphine on KCC2 expression at 24 h following viral/drug
exposure. The 6 h studies were assessed using two-way ANOVA with HIV (i.e., Tat1-86,
gp120, or HIVsup) and morphine treatments as factors. Interactions and main effects for
both were examined via simple main effects using a Bonferroni post hoc test to determine
individual group differences. Functional imaging studies were analyzed as above except
the assessment of VU0240551 was determined separately using a two-tailed Student’s t
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test. A two-tailed Student’s t test was also used to examine differences between Tat+ and
Tat− mice in western blots. Data were expressed as mean value ± standard error of the
mean. Analyses were considered significant if p < 0.05. Cook’s distance was used to
determine and remove outliers.
Results
HIV-1-infected PBMC supernatant reduces KCC2 immunoreactivity.
Previous studies have shown selective vulnerability of GABAergic neurons to HIV1 and Tat (Marks et al., 2016, Gelman et al., 2012a). Here, we examined KCC2
immunoreactivity to determine if [Cl−]i dysregulation might relate to GABAergic deficits.
To model the HIV-infected human brain, we exposed hNeurons to HIVsup. Experiments
show ~55 % of Hoechst+ cells in control groups are immunoreactive for KCC2 (Fig. 3.1A),
with significant reductions in co-expression when hNeurons were exposed for 6 or 24 h
to HIVsup at 250 - 500 pg/mL [p24] (but not 125 pg/ml [p24]) or 500 nM morphine (p <
0.01; n = 6) (Fig. 3.1A,B). Loss of KCC2 was not due to cell death in the exposure groups
examined as evidenced by continued MAP2 antigenicity and the LIVE/DEADTM
viability/cytotoxicity assay (Molecular Probes, Eugene, OR) (Fig. 3.8). Pretreatment (30
min prior to HIVsup ± morphine) with the KCC2 enhancer, CLP257 (10 µM), restored KCC2
immunoreactivity (p < 0.05; n = 6) (Fig 3.1B). These results suggest that Cl− regulation
and, therefore, GABA function may be altered in neurons of the HIV-1-exposed brain.
HIVsup and morphine interactions were examined at 125 pg/mL p24, but not found). This
interaction was not examined at 250 - 500 pg/mL p24 since cell death can occur with
morphine co-exposure at the higher p24 levels (Masvekar et al., 2015) and which might
be confounding for KCC2 immunoreactivity.
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The HIV proteins Tat and gp120 are both well-known to influence neuronal
hyperexcitability and progression of HAND (Nath and Steiner, 2014), so we tested their
contribution to the loss in KCC2 immunoreactivity induced by HIVsup. Since NMDAR and
CCR5 are respective major targets of Tat and gp120, we pretreated cultures with the
NMDAR antagonist AP5 (50 µM) and/or the CCR5 antagonist, MVC (50 nM). Independent
exposures showed that both significantly increase KCC2 immunoreactivity at 500 pg/mL
HIVsup and AP5 at 250 pg/mL HIVsup (p < 0.05, n = 5 – 6) with a trend towards rescue with
MVC at 250 pg/mL HIVsup (p = 0.061, n = 5 – 6) (Fig 3.1D). When combined, MVC and
AP5 are significantly different than either individually and completely restored KCC2
immunoreactivity (p < 0.01; n = 5 - 6) (Fig 3.1D), suggesting NMDAR and CCR5 as the
pathways mediating HIVsup-induced KCC2 reduction. Further examination revealed a
significantly increased KCC2 after AP5 exposure compared to MVC exposure suggesting
that while both CCR5 and NMDAR activation play a role, NMDAR is the dominant
pathway towards diminished KCC2 in this context (p < 0.01; n = 5). Both the pan-opioid
receptor antagonist, naloxone, and the selective MOR antagonist, CTAP, reversed KCC2
losses induced by morphine, suggesting MOR activation can suppress KCC2 activity (p
< 0.01; n = 6) (Fig 3.1C).
HIVsup ± morphine diminishes GABAAR mediated hyperpolarization.
The GEVI, Archon1, is a far-red-shifted, membrane-bound, voltage-sensitive,
opsin-based fluorescent protein that changes fluorescence intensity with membrane
potential. This high speed, noninvasive measurement of electrophysiological activity was
shown to be identical to patch-clamp recording of neuronal spiking (100 Hz) and
subthreshold millivolt scale activity (Piatkevich et al., 2018). To determine HIVsup ±
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morphine effects on GABAAR activation, we measured Archon1 activity in cultures
perfused with 100 µM GABA and GABABR antagonist, CGP55845 (2 µM) after 24 h
exposure to 125 - 500 pg/mL [p24] HIVsup ± morphine or to vehicle/UNF controls. Archon1expressing hNeuron control groups showed robust hyperpolarization with peak ΔF/F
deflection of −8.7 ± 0.5% during 115 s perfusion of 100 µM GABA, CGP55845 (Fig. 3.2).
hNeurons exposed for 24 h to varying concentrations of HIVsup (125 - 500 pg/mL p24) or
morphine (500 nM) showed 16 - 34% reductions of peak ΔF/F deflection during perfusion
(p < 0.01; n = 15 - 24), suggesting reduced hyperpolarization in response to GABAAR
activation (Fig. 3.2). Analysis revealed a main effect of CLP257 treatment in restoring
GABAAR-mediated hyperpolarization. A comparison of individual groups revealed that
CLP257 reversed the effects of 500 pg/mL [p24] HIVsup and morphine (p < 0.05; n = 15 24) (Fig. 3.2). Groups exposed to the KCC2 antagonist, VU0240551 (50 µM),
recapitulated results of HIVsup and morphine groups (28% ΔF/F reduction; p < 0.05; n =
15) (Fig. 3.2). We confirmed that ΔF/F changes above were, in fact, due to GABAAR
activation by perfusing GABA, CGP55845, and the noncompetitive Cl- channel blocker,
PTX (100 µM), and found no fluctuations in ΔF/F (Fig. 3.3). These results suggest that
loss of KCC2 activity due to HIVsup ± morphine exposure results in dysregulated [Cl−]i and
subsequent deficits in GABAAR activity, and that these deficits can be rescued by
maintaining KCC2 expression with CLP257.
HIV-1 proteins reduce KCC2 immunoreactivity.
Since HIVsup contains multiple inflammatory and viral factors found in the HIVinfected CNS, it served as a more translational model of neuronal injury. To determine
the contribution of individual viral proteins to effects seen with HIVsup, we exposed
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hNeurons to Tat1-86 and gp120 (R5-tropic, X4-tropic, and dual-tropic), both of which are
thought to be primary factors in neurodegenerative outcomes and HAND symptoms. We
first examined the effects of Tat1-86 exposure in isolation because NMDAR is a primary
target of Tat and its activation with regard to induction of KCC2 degradation is well-known
(Medina et al., 2014). Both morphine (500 nM) and Tat1-86 (50 – 100 nM) alone
significantly reduced percentages of Hoechst+ cells displaying KCC2 immunoreactivity,
after both 6 and 24 h exposure, compared to vehicle groups (p < 0.01; n = 6) (Fig. 3.4B,
C). Further, there was a significant interaction between Tat1-86 (50 nM) and morphine with
24 h co-exposed groups displaying exacerbated KCC2 loss (p < 0.05; n = 5 – 6),
suggesting signaling convergence. Again, cell death was not responsible for Tat1-86
effects since the number of MAP2+ cells was stable (Fig. 3.4A) and no increases in
dying/dead cells were evident using a cytotoxicity assay (Fig. 3.8). CLP257 significantly
rescued KCC2 immunoreactivity in Tat1-86, morphine, and co-exposed groups (p < 0.01;
n = 6) (Fig. 3.4C). Pharmacological blockade of NMDAR with AP5 rescued KCC2
immunoreactivity (Fig. 3.4C). These data suggest that Tat1-86 activation of NMDAR may
suppress KCC2 levels and may play a role in reducing the number of HIVsup-exposed
KCC2 immunoreactive hNeurons without causing their death.
Effects on KCC2 vary with gp120 tropism.
We tested concentration -dependent effects of gp120 (250 pM-1 nM) from three
different tropic strains of HIV. Exposure to gp120ADA (R5-tropic; p < 0.01; n = 6), but not
gp120IIIB (X4-tropic) (p = 0.23; n = 5) or gp120MN (dual-tropic) (p = 0.078; n = 5) strains,
significantly reduced KCC2 expression at both 6 h and 24 h compared to controls (Fig.
3.5 A, B). Further, there was a trend towards interaction with morphine and gp120ADA at
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the 500 pM level (p = 0.068; n = 6). The reduction in KCC2 immunoreactivity was not due
to cell death, although exposure to 1 nM gp120MN trended towards significant cell loss (p
= 0.06; Fig. 3.8). While KCC2 is a well-studied target of NMDAR activation in other
neuropathologic diseases, CCR5-mediated KCC2 regulation has not been described by
others. To validate that CCR5 activation triggered KCC2 loss, we pretreated cultures with
the CCR5 antagonist, MVC (50 nM), which maintained KCC2 expression (49.19 ± 1.2%;
p < 0.01; n = 5). Interestingly, pretreatment with CLP257 did not rescue KCC2
immunoreactivity in these experiments. These results describe a novel mechanism of
KCC2 regulation involving CCR5 and suggest that the activation of CCR5 by gp120ADA
may contribute to KCC2 reductions after HIVsup exposure.
HIVsup, Tat, and gp120 ± morphine did not alter NKCC1 immunoreactivity.
NKCC1 acts in opposition to KCC2 and is the primary neuronal Cl- transporter in the
immature brain. To examine another potential route of neuronal Cl- dysregulation, we
immunostained hNeurons for NKCC1 after 24 h exposure to 125 – 500 pg/mL [p24]
HIVsup, 10 – 100 nM Tat, and 250 – 1000 pM gp120 ± morphine. NKCC1 was not
detectable with exposure any of the viral factors or morphine at any of the concentrations
examined (n = 4) (data not shown).
HIV-1 proteins reduce inhibitory potential of GABAAR activation.
We next examined the functional effects of Tat1-86, gp120ADA, and morphine on
GABAAR-induced inhibition by expressing the intracellular Ca2+ reporter GCaMP6f in
hNeurons using AAV1.hSyn.GCaMP6f.WPRE. GABAAR-mediated inhibition was
examined in these cells by recording neuronal Ca2+ activity during perfusion of BrainPhys
solution containing 100 µM GABA, 25 µM glutamate, and 2 µM CGP55845 for 55 s and
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quantifying resultant neuronal spiking (the total number of significant Ca2+ transients
during 55 s recording period). Analysis revealed a significant increase in 50 nM Tat1-86
and morphine groups, without interaction comparedto vehicle (p < 0.01; n = 15 – 21) (Fig.
3.6B). Thus, Tat1-86 and morphine independently reduced the inhibitory potential of
GABAAR activation. Pretreatment with CLP257 ameliorated Tat1-86 and morphine effects
(p < 0.01; n = 15 - 21), suggesting rescue of inhibitory activity in these groups, consistent
with immunoreactivity results showing restored levels of KCC2. We also found
disinhibition of hNeurons, as determined by significantly increased Ca2+ spiking in groups
exposed to 500 pM gp120ADA (Fig. 3.6B). Three-way ANOVA revealed a main effect of
gp120ADA regardless of CLP257 or morphine application (p < 0.05; n = 15 - 18).
Pretreatment with MVC showed a strong tendency to prevent gp120-induced excitation
presumably by retaining/restoring KCC2 function (p = 0.059). Consistent with
immunoreactivity results, these results suggest a failure of CLP257 to maintain KCC2
expression following gp120ADA exposure and, thus a failure to restore the inhibitory effects
of GABAAR activation. Selectively inhibiting KCC2 with VU0240551 recapitulated the
effects of Tat1-86 or gp120ADA ± morphine effects (n = 15, p < 0.01) independently
confirming the role of KCC2 in the overexcitation. These results suggest that hNeurons
become disinhibited after Tat1-86 or gp120ADA ± morphine exposure due to a loss of KCC2
activity and that pharmacological maintenance of KCC2 can prevent or rescue the
deleterious effects of Tat and/or morphine.
Tat expression reduces KCC2 in the striatum of Tat-transgenic mice.
HIV-1 Tat transgenic mice show neuropathology and behavioral deficits similar to
PWH (Schier et al., 2017, Fitting et al., 2013). To examine if KCC2 abnormalities found
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in culture could be seen in Tat-transgenic mice, we performed western blot analysis of
striatal tissue after two weeks of Tat induction by DOX. Tat+ mice showed a significant
decrease in total KCC2 levels compared to Tat− control mice (Fig. 3.7) (p < 0.05; n = 12).
These results confirm that chronic Tat exposure induces KCC2 loss in vivo as well as in
cultured hNeurons.
Discussion
Previous studies including human post-mortem (Buzhdygan et al., 2016, Gelman
et al., 2012a) and in vivo rodent studies (Marks et al., 2016, Xu et al., 2016, Fitting et al.,
2013) have shown selective changes in GABAergic markers and function, driving an
emerging concept that disrupted GABAergic transmission may be central to the
development of HIV-related CNS dysfunction. Our data strengthen this perspective by
demonstrating that KCC2 levels and subsequent GABAergic activity are diminished by
an infective, HIV+ environment and by exposure to gp120ADA in vitro or HIV-1 Tat, both in
vitro and in vivo. Importantly, HIV-infected individuals demonstrate a loss of GABAergic
markers without the loss of GABAergic neurons (Buzhdygan et al., 2016) as seen in the
present study. Taken together, our data along with findings from other investigators
suggest that there may be an overall loss of inhibition via reduced inhibitory synapses
and/or GABAergic function, and as we demonstrate here, diminished hyperpolarization
at remaining inhibitory synapses caused by deficits in KCC2.
Endogenous levels of chemokine (C-C motif) ligand 5 (CCL5) are almost
undetectable in the healthy CNS, but dramatic increases are found in several
neuroinflammatory disorders (Louboutin and Strayer, 2013) including HAND (El-Hage et
al., 2005, Letendre et al., 1999). In multiple sclerosis, CCL5 is elevated during early
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stages of the disease and is correlated with hyperexcitability (Sorensen et al., 1999, Mori
et al., 2016). Our results demonstrate KCC2 as a target of CCR5 activation that may
underlie this hyperexcitability. Targeting CCR5, perhaps with MVC, should be further
investigated for therapeutic potential in multiple sclerosis and in other disorders in which
elevated CCL5-CCR5 signaling may be operative, such as in neuroHIV (Kim et al., 2018).
Additionally, our results using the MOR-selective antagonist, CTAP (Fig. 3.1C)
demonstrate that neuronal KCC2 expression is a target of MOR activation. It is important
to note that we have used a mixed neuron-astrocyte culture model. Outcomes may thus
be due to direct activation of neuronal MOR, or a secondary effect of MOR activation on
astroglia. Our results only demonstrated an interaction between morphine and viral
proteins at the 24 h timepoint. Our previous studies have shown neurotoxic interactions
between morphine and HIV/viral proteins at 24 – 72h and also that neurotoxicity was
largely if not completely driven by glia (Zou et al., 2011) [or similarly by CCR5 deletion
from glia (Kim et al., 2018)]. Thus, astrocytes may be acting as the intermediary through
which MOR activation leads to neuronal KCC2 loss in the data presented here. Overall,
our implication of MOR in KCC2 loss is in line with previous findings that GABAAR
activation on neurons in the ventral tegmental area of rats switches from an inhibitory to
excitatory signal during the development of opiate dependency (Laviolette et al., 2004,
Vargas-Perez et al., 2009), and that KCC2 loss contributes to states of opiate withdrawal
and morphine-induced hyperalgesia via mechanisms involving microglia-mediated BDNF
release and subsequent TrkB activation (Ferrini et al., 2013, Ferrini et al., 2017, Taylor et
al., 2016). Further, we found an exacerbation of KCC2 losses at 50 nM Tat with coexposure to morphine, suggesting that opiates and HIV protein interactions may similarly
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occur in the CNS and underlie the increased incidence/severity of HAND that has been
noted in PWH who abuse opiates (Byrd et al., 2011, Bell et al., 2006, Carrico, 2011, Smith
et al., 2014).
Interestingly, CLP257 was able to maintain KCC2 expression and functional
response of hNeurons to Tat, but had no effect on gp120-exposed groups. While many
factors regulate KCC2 activity/degradation, the mechanism by which CLP257 preserves
KCC2 activity remains elusive. KCC2 stability is regulated by phosphorylation at multiple
sites. For example, phosphorylation of S940 or T1007 by protein kinase C and WNK
increases and decreases KCC2 membrane stability, respectively (Lee et al., 2011, Inoue
et al., 2012). NMDAR activation can lead to protein phosphatase 1 activation and S940
dephosphorylation leading to decreased membrane localization and subsequent calpaininduced KCC2 degradation in the cytoplasm (Lee et al., 2011). Thus, there are several
mechanisms that may underlie the effects of CLP257. gp120 and Tat may have
differential effects on one or more of these pathways, resulting in these inconsistencies.
MVC, an FDA-approved CCR5 antagonist commonly prescribed to HIV-infected
individuals to prevent HIV from binding to this co-receptor, was able to rescue both KCC2
expression and functional responses to GABAAR activation in gp120ADA-exposed
hNeurons. Thus, MVC treatment might prevent gp120ADA-induced KCC2 loss upstream
of CLP257 and could be considered more widely for PWH with HAND symptomology.
Neuronal electrophysiological properties govern CNS function, and elucidating
deficits at the cellular level can identify circuitry imbalances that underlie neurological
disorders. To study electrophysiological responses in HIV-1 exposed neurons, we used
the GEVI, Archon1. This noninvasive interrogation has the advantages of allowing
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ensemble activity to be studied both in vitro and in vivo, with the capability of tracking
specific neurons long-term. This is a particularly useful alternative to traditional
electrophysiology when biosafety is a concern. Most of the experiments here utilized
acute exposure paradigms (6 and 24 h). While this approach allowed us to uncover novel
targets and subsequent functional responses in primary human neurons, PWH are
exposed to these factors over a much longer timeframe. Thus, we began to validate the
observed changes using a chronic in vivo model and found reduced KCC2 in the striatum
of Tat+ transgenic mice after 2 weeks of Tat exposure. Further studies are underway to
test the effectiveness of a CLP257 prodrug (CLP290) to reverse KCC2 loss, the resultant
electrophysiological and behavioral changes observed with Tat and/or CLP290
exposures, and any preferential vulnerability between the prominent neuronal subtypes
in the striatum (dopamine D1 receptor-expressing vs. dopamine D2 receptor-expressing)
to KCC2 loss. Interestingly, the loss of the expression of GABAergic markers is inversely
correlated with increases in dopamine D2 receptor (DRD2L) in PWH and increases in
DRD2L in the prefrontal cortex positively correlated with the development of HAND
(Gelman et al., 2012b, Buzhdygan et al., 2016). HIV-induced neurocognitive detriments
vary among individuals, and length of exposure is likely a contributing factor along with
age, genetics, comorbidities (including drug use), and the particular strains of HIV
present. We used the HIVBaL strain to generate HIVsup as R5 tropism is prominent in the
CNS (Schnell et al., 2011). We also began to address viral heterogeneity by comparing
effects of three different gp120 strains. Results here suggest that R5-tropic strains may
be more likely to disrupt GABAergic circuitry. CSF viral titers and levels of HIV-1 Tat have
been shown to vary among infected individuals whose blood titers are well-controlled
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(Johnson et al., 2013, Henderson et al., 2019). Thus, we expect that levels of viral proteins
and inflammation within the brain parenchyma must also vary among PWH. As these
levels are not easily measured, our experimental paradigm may over- or underestimate
CNS exposure levels in HIV-infected individuals.
Similar situations of disinhibition through dysregulated [Cl−]i appear to contribute
significantly to hyperexcitability in other neurological disorders, and restoration of KCC2
with CLP257 or its prodrug, CLP290, has shown promise in reversing the hyperexcitability
in models of these disorders (Chen et al., 2018, Ferrini et al., 2017). Overall, our studies
further implicate KCC2 in novel ways that could have broad impact for human health. We
established KCC2 and upstream pathways as promising therapeutic targets to restore
GABAergic function and to treat the symptoms of HAND, and this approach may be
particularly relevant for PWH that use opiates. We also identified KCC2 as a novel link
underlying hyperexcitability in conditions that involve elevated CCL5 and/or CCR5
activation in the CNS. Our results also highlight that opiate drugs of abuse may
independently dysregulate KCC2 levels to cause GABAergic dysfunction. This finding has
significance for the large population of opiate abusers who are not infected with HIV.
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Figure 3.1. HIVsup and morphine significantly reduce the percentage of cells
immunoreactive for KCC2. Treatment for 6 h (A) or 24 h (B) with 250 – 500 pg/mL
[p24] HIVsup ± morphine significantly reduces the number of KCC2 immunoreactive
cells (†p < 0.01 for respective controls; n = 6). CLP257 (blue) rescued this effect across
all groups (*p < 0.05, n = 6). Naloxone and CTAP both antagonized the effects of
morphine (C), suggesting the involvement of MOR (*p < 0.01; n = 6). AP5 (orange)
restored KCC2 immunoreactivity after 250 – 500 pg/mL HIVsup exposure while MVC
(maroon) significantly increased KCC2 in 500 pg/mL (*p > 0.05, n = 5 – 6). A trend
towards MVC rescue of KCC2 immunoreactivity was found at 250 pg/mL HIVsup (p =
0.061, n = 5 – 6). Co-exposure of HIVsup with both AP5 and MVC fully restored KCC2
levels, suggesting NMDAR and CCR5 as the primary pathways of HIVsup-mediated
KCC2 reduction. Representative images for KCC2 immunofluorescence of vehicle,
morphine, and morphine + CTAP-treated hNeurons. Scale bar = 50 µm (E).
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Figure 3.2. HIVsup and morphine decrease GABAAR-mediated hyperpolarization.
(A) Representative traces of 500 pg/mL [p24] HIVsup treated (red) and vehicle control
(black) during GABA and CGP55845 perfusion (115 s). Arrow is representative of the
diminished hyperpolarization quantified in the bar graph. (B) Bar graph shows peak
ΔF/F deflection from each treatment groups normalized as a percentage of vehicle
control corresponding to that sample during 115 s perfusion of 100 µM GABA and
CGP55845. hNeurons expressing Archon1 exposed to 125 - 500 pg/mL [p24] HIV ±
morphine shows reduced hyperpolarization (†p < 0.01, n = 15 - 21) and/or UNF (ǂp <
0.01, n = 15 - 21). Analysis revealed a main effect of CLP257 and group comparisons
showed that CLP257 significantly reversed the effects of 500 pg/mL HIVsup and
morphine groups (blue) (*p < 0.05, n = 15 - 21). Further, 2 h treatment with
VU02440551 showed similar results as HIVsup ± morphine groups, significantly
reducing percentage of cells immunoreactive for KCC2 (#p < 0.05, n = 15 - 21),
suggesting that effects of HIVsup and morphine are due to loss of KCC2 activity. Data
were analyzed from 15 - 21 cells from 5 – 6 separate tissue samples per group.
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Fig. 3.3. Validation of Archon1. Representative trace of Archon1 activity in hNeuron
during perfusion of 100 µM GABA and CGP55845 (Top) and 100 µM GABA and
CGP55845 and PTX (bottom). Antagonizing GABAAR and GABABR prevented ΔF/F
changes, suggesting that fluorescence shifts seen in the top trace and Fig. 3.2 are due
to GABAAR activation (n = 9).
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Figure 3.4. hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ±
morphine. (A) Representative images of hNeuron cultures immunolabeled for MAP2
and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50
nM Tat1-86 and 50 nM Tat1-86 + morphine. Rescue is seen in 50 nM Tat1-86 + AP5 (scale
bar = 50 µm). (B, C) The percentage of cells immunoreactive for KCC2. Both 6 h (B)
and 24 h (C) exposure to 50 - 100 nM Tat1-86 ± morphine results in significant decrease
in KCC2 immunoreactivity compared to their respective controls (†p < 0.01; n = 6 – 7).
Further, a significant interaction between morphine and Tat1-86 was found at the 50 nM
Tat1-86 level after 24 h exposure (#p < 0.05). Application of CLP257 (blue) and AP5
(white) showed significant restoration of KCC2 immunoreactivity across all groups and
Tat1-86 exposed groups, respectively (*p < 0.01).
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Figure 3.5. gp120 ADA reduces KCC2 immunoreactivity. (A, B) Bar graphs
quantifying percentage of cells immunoreactive to KCC2. Both 6 h (A) and 24 h (B)
exposures to 500 pM - 1 nM gp120 ADA significantly reduced the percentage of KCC2
immunoreactive cells compared to their respective controls (†p < 0.01; n = 6), while
gp120 IIIB or gp120 MN had no significant effect on KCC2 expression. Interestingly,
CLP257 co-exposure failed to maintain KCC2 immunoreactivity in gp120 ADA
exposed groups, but MVC showed significant rescue (*p < 0.05; n = 5 - 6), suggesting
that CCR5 activation is responsible for gp120 loss.
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Figure 3.6. Tat1-86, gp120 ± morphine exposure decreased GABAAR mediated
inhibition. (A) Representative 30 s sample GCaMP6f traces of vehicle (top) and 50
nM Tat1-86 + morphine (bottom) exposed hNeurons during 25 µM glutamate, 100 µM
GABA, and CGP55845 perfusion. (B) Exposure to 50 nM Tat1-86 ± morphine (500 nM)
resulted in significantly increased Ca2+ transients measured by GCaMP6f activity
during 55 s perfusion of 25 µM glutamate, 100 µM GABA, and CGP55845 compared
to control (†; p < 0.05; n = 15 - 21). CLP257 (blue) rescued these effects (*; p < 0.01;
n = 15 - 21). Exposure to 500 pM gp120 ADA showed significant increase in neuronal
activity, regardless of CLP257 or morphine cotreatment (†; n = 15 - 21; p < 0.05). MVC
exposure trended towards reversing gp120 effects (p = 0.059, n = 18). KCC2
antagonist, VU02440551 recapitulated results of Tat1-86, gp120, and morphine,
suggesting that these effects are due to loss of KCC2 activity (#p < 0.01, n = 15). Ca2+
transients were considered significant and counted when the spike amplitude was > 4
SD above background activity (determined 2.5 s prior to perfusion; red line) and
returned to within 0.5 x standard deviation of background activity (blue line).
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Figure 3.7. Tat+ mice show reduced striatal KCC2 compared to control Tat- mice.
Two weeks of Tat expression significantly reduced the amount of KCC2 detected by
western blot (n = 12; p < 0.05). Data are displayed as KCC2 intensity normalized to
GAPDH.
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Fig. 3.8. HIVsup, Tat, gp120 ± morphine effects on cellular viability. Treatments for
24 h of 125 – 500 pg/mL [p24] HIVsup, 50-100 nM Tat ± 500 nM morphine had no
significant effect on cellular viability (A, B). Treatments for 24 h of 250 – 1000 pM
gp120 ADA and 1 nM gp120 IIIB do not affect cellular viability while 1 nM gp120
trended towards significantly increasing cellular death (C). n = 4.
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Chapter 4
Restoration of KCC2 membrane localization in striatal D2R-expressing medium
spiny neurons rescues behavioral deficits in HIV Tat-transgenic mice
(This chapter is in preparation for publication)

Abstract
People infected with HIV (PWH) are highly susceptible to hippocampal and striatal
damage from the neurotoxic HIV protein, transactivator of transcription (Tat). Memory and
motor impairment are common among these patients, likely as behavioral manifestations
of damage to these brain regions. GABAergic dysfunction from HIV infection and Tat
exposure has been well documented. We recently demonstrated that the neuron specific
Cl- extruder, K+ Cl- cotransporter (KCC2), is diminished after exposure to HIV proteins
resulting in disrupted GABAAR-mediated hyperpolarization and inhibition. Here, we
utilized doxycycline (DOX)-inducible, GFAP-driven Tat transgenic mice to further explore
this phenomenon. We found no changes in hippocampal KCC2, but a significant decrease
in the striatum associated with hyperlocomotion in the open field assay in mice expressing
the Tat transgene with two wks of DOX treatment. We were able to restore KCC2 activity
and baseline locomotion with the KCC2 enhancer, CLP290. Additionally, we found that
CLP290, whose mechanism of action had yet to be described, acts to restore
phosphorylation of serine 940 resulting in increased KCC2 membrane localization. We
also examined neuronal subpopulation contributions to the noted effects and found that
dopamine receptor D2-expressing MSNs are selectively vulnerable to Tat-induced KCC2
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loss with no changes seen in dopamine receptor D1-expressing MSNs. These results
provide a mechanism underlying motor impairment in PWH and suggest that targeting
KCC2, perhaps with CLP290, is a viable treatment for those with HIV-associated
neurocognitive disorders.
Introduction
While the advent of combined antiretroviral therapy (cART) has greatly improved
the prognosis of HIV-1 infection, quality of life issues remain. One of the most prevalent
being HIV-associated neurocognitive disorders (HAND), with about half of people infected
with HIV (PWH) experiencing detriment in varying neurocognitive domains including
memory recall and sensorimotor function (Heaton et al., 2010, Antinori et al., 2007).
These cognitive and behavioral alterations are likely due to synaptodendritic damage and
circuitry disruption caused by direct and secondary damage from HIV proteins and
persistent neuroinflammation (Masliah et al., 1997, Brailou et al., 2008, Tavazzi et al.,
2014, Alakkas et al., 2019). While neurons are not infected by HIV, both microglia and
astrocytes can be infected and release viral proteins and inflammatory factors damaging
neurons as bystanders. Both the hippocampus and striatum seem to be particularly
vulnerable to these factors in humans and in vivo models of HAND (Fitting et al., 2010,
Marks et al., 2016, Fitting et al., 2013, Gelman et al., 2006, Chang et al., 2008, Maki et
al., 2009, Alakkas et al., 2019).
The HIV-1 protein, transactivator of transcription (Tat), is a primary mediator of
HIV-induced CNS degeneration, is secreted by infected cells, and its expression is seen
in PWH even when receiving effective cART (Henderson et al., 2019). Use of the
doxycycline (DOX)-inducible, glial fibrillary acidic protein (GFAP)-driven Tat transgenic
75

mouse has been used to study the neuropathological features of Tat exposure in vivo and
recapitulates many of the behavioral abnormalities seen in HAND patients (Paris et al.,
2014b, Hahn et al., 2016, Fitting et al., 2012, Marks et al., 2016, Fitting et al., 2013, Carey
et al., 2012, Kim et al., 2003). Tat is capable of inducing proinflammatory phenotypes in
both astrocytes and microglia, promoting neuroinflammation and has direct neuronal
targets. Through activation of NMDAR, AMPAR, L-type voltage gated Ca2+ channels, Tat
can induce focal disruptions in Ca2+ homeostasis resulting in loss of synaptodendritic
complexity (Fitting et al., 2014, Schier et al., 2017, Fitting et al., 2010, Chandra et al.,
2005, Napier et al., 2014).
Hyperexcitability is a hallmark of the HIV-exposed CNS and excessive glutamate
release and reduced clearance have been well studied (Longordo et al., 2006, Pappas et
al., 1998, Wang et al., 2003, Musante et al., 2010). Accumulating evidence has also
revealed the importance of GABAergic disruption in hyperexcitability. Human postmortem
tissue from HAND patients as well as in vivo models of HAND display reduced GABAergic
markers (Fitting et al., 2013, Marks et al., 2016, Buzhdygan et al., 2016, Gelman et al.,
2012a) and functionality (Xu et al., 2016) as we also demonstrated in Chapter 3. K+ -Clcotransporter 2 (KCC2) is neuron-specific and functions to extrude Cl- to maintain low the
intracellular levels upon which GABAAR mediated hyperpolarization is predicated.
Membrane localization and, therefore, functionality of KCC2 is mediated by several
phosphorylation sites (Cordshagen et al., 2018). One well-studied residue, serine 940
(S940), can be phosphorylated by protein kinase C (PKC) to increase membrane stability
and localization and can be dephosphorylated by protein phosphatase 1 (PP1) resulting
in internalization (Lee et al., 2007, Lee et al., 2011). A loss of KCC2 and/or its membrane
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localization results in diminished GABAAR-mediated hyperpolarization/inhibition and has
been found to be a mediator of neuronal disinhibition in several neurological disorders
(Lizhnyak et al., 2019, Arion and Lewis, 2011, Boulenguez et al., 2010, Chen et al., 2017a,
Dargaei et al., 2018, Chen et al., 2017b). Importantly, these deficits have been rescued
in many cases with the KCC2 activity enhancer, CLP257, and its prodrug, CLP290,
although the mechanism underlying their mechanism of action remains elusive. We have
recently shown that KCC2 is a target of the HIV proteins Tat and gp120 in primary human
neurons in vitro and in an in vivo model of neuroHIV and, thus, may be implicated in
neuronal dysfunction underlying HAND.
The striatum is composed primarily of dopamine receptor D1 (D1R)-expressing
medium spiny neurons (MSNs) and dopamine receptor D2 (D2R)-expressing MSNs. This
area is particularly vulnerable to HIV-induced damage in PWH (Gelman et al., 2006,
Alakkas et al., 2019), and in vivo models of neuroHIV (Fitting et al., 2014, Schier et al.,
2017, Fitting et al., 2010). Striatal MSNs, particularly those expressing D2R (Schier et al.,
2017) are vulnerable to Tat-induced spine reductions due to dendritic Ca2+ influx (Fitting
et al., 2014). Given striatal vulnerability to Tat-induced KCC2 loss, and clinical evidence
demonstrating motor deficits in PWH, we sought to further explore this phenomenon by
examining potential motor dysfunction caused by diminished striatal KCC2, whether these
effects were reversible using CLP290, and if there was preferential vulnerability between
D1R-expressing or D2R-expressing MSNs. We found a loss of KCC2 selectively in D2Rexpressing MSNs of the striatum of mice expressing the Tat transgene (Tat+) vs those
without the transgene (Tat-), correlating with motor hyperactivity after two wks DOX
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administration. Additionally, we were able to rescue phosphorylation of S940-KCC2,
membrane localization of KCC2, and motor activity with CLP290 oral gavage.
Methods
Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee
at Virginia Commonwealth University and were in accordance with ethical guidelines
defined by the National Institutes of Health.
Mice used for behavioral and western blot experiments were male, doxycycline (DOX)inducible, GFAP driven HIV-1 Tat-transgenic mice aged 10 – 12 weeks. Mice that
expressed the rtTA and Tat transgenes (Tat+) or mice only expressed rtTA without Tat
(Tat-), were fed DOX-containing chow (6 mg/g, Harlan indianapolis, IN) for two weeks
prior to experimentation.
Tat+ and Tat- mice were crossed with B6.Cg-Tg (Drd1a-tdTomato)6Calak/J line 6 mice
(#016204; The Jackson Laboratory) or Drd2-eGFP (#036931 – UCD; Mutant Mouse
Resource and Research Centers) mice (Ade et al., 2011) to detect D1R-expressing and
D2R-expressing

neuronal

subpopulations,

respectively,

and

were

used

for

immunohistochemistry (IHC)/colocalization and electrophysiological experiments.
All mice were housed two to five per cage with ad libitum access to food and water in a
temperature- and humidity-controlled facility on a 12:12 h light – dark cycle.
Drug administration
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Mice were treated with either the KCC2 enhancer, CLP290 (50 mg/kg; Aobious), freshly
suspended in dimethyl sulfoxide (DMSO) and 20% 2-hydroxypropyl-β-cyclodextrin
(HPCD; Tocris) or vehicle once per day (morning) by oral gavage (200 µL total volume)
for seven days during the second week of DOX administration.
Behavior
After two weeks DOX administration, mice were assayed for locomotor effects with the
open field assay by placing mice in the top left corner of a 40 x 40 x 35 cm Plexiglas box
and recording their activity for 20 min. Rearing responses were recorded when the animal
breaks the array of photo-beams and total distance and time spent in center was recorded
and encoded using the ANY-maze behavioral tracking system (Stoelting).
Western Blot
KCC2 was quantified by western blot of striatum from Tat+ and Tat- mice. Freshly
harvested whole striata were homogenized in RIPA buffer (Sigma) with HALTTM Protease
& Phosphatase inhibitor Cocktail (Thermo Fisher) to prevent protein degradation. Lysates
were separated and stored at -80º C. Protein concentration was measured using BCA
protein assay (Pierce, Rockford, IL). 40 µg lysate per sample were loaded into 4 – 20%
Tris-HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred to
PVDF membranes (Bio-Rad) and probed with anti-KCC2 (1:2000; Protein Tech,
Rosemont, IL) or anti-pS940 KCC2 and GAPDH (1:2000; Abcam) antibodies. KCC2 and
GAPDH proteins were detected measuring fluorescent signal from Alexa Fluor 647 and
488-conjugated secondary antibodies (1:1000; Thermo Fisher), respectively. pS940KCC2 proteins were detected using pS940-KCC2 specific antibody (1:2000; Novus Bio),
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horseradish peroxidase (HRP; Southern Biotech; Birmingham AL) and SuperSignalTM
West Femto Maximum Sensitivity Substrate (Thermo Fisher).
Membrane bound KCC2 was examined by western blot by first performing membrane
fractionation on striata from Tat transgenic mice. Briefly, tissue was homogenized in lysis
buffer (4 mM HEPES (N-2-hydroxyethylpiperazine-N-3-ethane sulfonic acid; Thermo
Fisher Scientific), 320 mM sucrose, 5 mM EDTA (ethylenediaminetetraacetic acid;
Thermo Fisher Scientific), and HALTTM Protease & Phosphatase inhibitor cocktail
(Thermo Fisher Scientific)), centrifuged at 100,000 x g, and the pellet containing
membrane fraction was resuspended in lysis buffer and stored at -80º C. Protein
concentration measurement and western blot for these samples were performed as
above, except that a 20-µg lysate load was used per sample lane. KCC2 was normalized
to total lane protein detected by RevertTM 700 Total Protein Stain (LI-COR, Lincoln, NE),
and Alexa Fluor 488-conjugated secondary antibodies (Thermo Fisher) were used to
detect KCC2.
IHC
After two wks DOX administration, Drd1a-tdTomato/Drd2-eGFP X Tat+/Tat- mice were
fixed by cardiac perfusion with 4% paraformaldehyde (PFA). Brains were then dissected,
submerged in 4% PFA for 24 h, washed in PBS, and sequentially placed in 10%, 20%,
and 30% sucrose for 24 h each before being embedded in OCT. Serial 20 µM sections
were cut on a cryostat, thaw mounted, dried, and stored frozen at -80º C. IHC was then
performed by permeabilizing for 30 min (0.01% Triton-X100), blocking for 1 h, and
overnight incubation with primary antibody for KCC2 (1:500; Protein Tech) at 4º C. The
following day, Drd1a-tdTomato and Drd2-eGFP sections were washed and incubated for
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1 h with 488 and 594 Alexa-Fluor conjugated secondary antibodies (1:1000; Invitrogen,
Carlsbad, CA), respectively, for 1 h. Hoechst 33342 (1:10000, Thermo Fisher) was used
to identify nuclei and weighted coverslips were adhered with ProLongTM Gold Antifade
Mountant (Thermo Fisher).
Colocalization
To visualize KCC2 immunofluorescence and tdTomato or eGFP, Z-stack images were
obtained with a Zeiss LSM 700 confocal module configured to an Axio Observer Z.1 with
20 x objective and Zen 2010 software (Zeiss Inc., Thornwood, NY). 3D reconstruction
and colocalization between KCC2 and tdTomato (D1R-expressing MSNs) or eGFP (D2Rexpressing MSNs) was performed with Imaris software (Bitplane, South Windsor, CT).
Colocalization thresholding was determined using secondary control (without primary
antibody incubation) sections from the same mice. Thresholds were equivalent across all
mice and set to virtually no colocalization (< 1%) between tdTomato/eGFP and KCC2
immunofluorescence for control slices. Colocalization results are displayed as the
percentage of voxels with tdTomato or eGFP fluorescence colocalized with voxels
containing KCC2 immunofluorescence.
Statistics
A two-tailed Student’s t test was used to examine potential differences in KCC2 western
blots between Tat+ and Tat- mice and for colocalization experiments. Two-way analysis
of variance (ANOVA) was used to examine behavioral assays and western blots with drug
(CLP290/Vehicle) and genotype (Tat+/Tat-) as factors. Interactions and main effects were
examined via simple main effects using Bonferroni post hoc test to determine group
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differences. Data are displayed as mean value ± standard error of the mean. Results were
considered significant when p < 0.05. All statistical analyses were performed in R.
Results
Two weeks of DOX-induced Tat expression reduces total KCC2 in the striatum of
Tat-transgenic mice.
Clinical evidence and results from Tat-transgenic mice have demonstrated
vulnerability of the striatum and hippocampus to HIV- and Tat-induced neuropathology.
Thus, we examined total KCC2 by western blot in hippocampal and striatal tissue from
Tat-transgenic mice with DOX administration for two and four weeks (striatum) or two,
four, and eight weeks (hippocampus). There was no difference found in hippocampus at
any time points (two wk DOX: p = 0.82, n = 6; four wk DOX: p = 0.51, n = 6; eight wk
DOX: p = 0.65, n = 7) (Fig 4.1A). Nor were significant differences found in the striatum
after four wks of DOX-induced Tat exposure (p = 0.28, n = 6) (Fig 4.1B). However, we
found a significant decrease in total KCC2 in the striatum of Tat+ mice compared to Tatmice on DOX for two wk (p = 0.001, n = 11 - 12) (Fig 4.1B; data also shown in Fig 3.8,
included here for clarity). These results suggest that the striatum is vulnerable to Tatinduced KCC2 loss in a biphasic, or possibly, more complex manner. This suggests that
striatal circuitry may be disrupted due to deficits in GABAAR-mediated inhibition after two
wks of Tat exposure.
Tat expression reduced total KCC2 in the striatum and CLP290 rescued pS940KCC2 and KCC2 membrane localization.
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To determine if striatal KCC2 loss could be reversed, we treated Tat+ and Tatmice with 50 mg/kg CLP290 or vehicle by oral gavage once per day during the second
week of DOX administration. Western blot analysis revealed a main effect of genotype to
reduce total KCC2 in the striatum of Tat+ compared to Tat- mice without interaction (main
effect: p = 0.002, n = 12 – 18), suggesting that Tat induction diminished the presence of
KCC2 and that CLP290 failed to rescue total KCC2 levels (Fig 4.2A). Membrane
localization of KCC2 and, thus, Cl- extrusion activity is promoted by phosphorylation of
S940. We sought to determine if CLP290 treatment was capable of rescuing
phosphorylation of S940 (pS940). Analysis of western blot of striata harvested from Tat+
and Tat- mice treated with either CLP290 or vehicle for pS940-KCC2 revealed a drug by
genotype interaction (p < 0.05, n = 8 – 12). Investigation of simple main effects determined
that Tat expression reduced pS940-KCC2 and administration of CLP290 rescued this
effect (p < 0.05; n = 8 - 12) (Fig 4.2B) and, thus, likely restores membrane localization
and Cl- extrusion capacity of KCC2. To confirm this, we performed a membrane fraction
separation and western blot for KCC2 and found that membrane localization of KCC2
was, again, significantly reduced by two wks Tat exposure and was, in fact, restored by
CLP290 administration (p < 0.05, n = 8 – 9) (Fig 4.2C). These data suggest that CLP290
is able to rescue the functional state of KCC2 and provide insight into a mechanism
involving phosphorylation of S940 that may underlie the effects of CLP290.
Tat+ mice displayed hyperactive locomotion with rescue seen via CLP290
administration.
To determine potential behavioral manifestations of Tat effects on disrupted striatal
activity, we assayed locomotor activity of Tat+ and Tat- mice treated with either CLP290
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or vehicle with the open field test. Significant increases were found in the distance
travelled and rearing number in the Tat+/Veh groups with rescue in the Tat+/CLP290
group (p < 0.05, n = 8 – 9) (Fig 4.3 A, B). These results suggest motor hyperactivity in
Tat+ animals with CLP290 restoration of KCC2 membrane localization sufficient to
restore baseline activity. We also examined the time spent in center zone as one measure
of anxiety-like behavior and found no significant differences (n = 8 – 9) (Fig 4.3C). Overall,
these results suggest that diminished KCC2 activity in the striatum, likely resulting in
neuronal disinhibition, leads to excessive locomotion.
Previous work in our lab demonstrated a loss in dendritic spines selectively in D2Rexpressing MSNs of Tat+ mice (Schier et al., 2017). Given the biochemical and behavioral
results presented here and the role KCC2 plays in dendritic spine maintenance (Li et al.,
2007, Fiumelli et al., 2013), we hypothesized that D2R-expressing MSNs are selectively
vulnerable to Tat-induced KCC2 loss, contributing towards disrupted striatal circuitry
manifesting as hyper locomotor activity.
D2R-expressing MSNs show enhanced KCC2 loss in response to Tat induction
compared to their D1R-expressing counterparts.
We crossed Tat+ and Tat- mice with Drd1a-tdTomato and Drd2-eGFP mice to
allow for independent examination of D1R-expressing and D2R-expressing MSNs to
determine if there is a preferential vulnerability of D1R or D2R-expressing MSNs to Tatinduced KCC2 loss. To visualize KCC2 colocalization with tdTomato (D1R-expressing
MSNs) or EGFP (D2R-expressing MSNs) we performed IHC with antibodies specific for
KCC2 and either 488 or 594 secondary antibodies, respectively. Z stacks of striata were
obtained and 3D reconstruction and subsequent colocalization analysis was performed
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with Imaris. We found a loss of KCC2 colocalization with eGFP in Tat+ x Drd2-eGFP mice
compared to Tat- x Drd2-eGFP mice (p < 0.05, n = 8) and no significant changes in KCC2
colocalization between Tat+/Tat- x Drd1a-tdTomato mice (n = 3 – 12) (Fig 4.4). It does
not appear that there is overt, total loss of KCC2 in some D2R-expressing MSNs, thus,
there is likely a more subtle decrease across a large proportion. Particularly noticeable is
that somatic KCC2 staining appears primarily around the membrane in D1R-expressing
MSNs and Tat- D2R-expressing MSNs (yellow arrows, Fig 4.4), this localization is lost in
Tat+ D2R-expressing MSNs (white arrows, Fig 4.4), suggesting shifted reversal potential
of Cl- and diminished hyperpolarization in this population of neurons. Overall, data from
these experiments suggest a preferential vulnerability D2R-expressing MSNs to Tatinduced KCC2 loss and provide some insight to the circuit disruption underlying the
behavioral abnormalities found above.
Discussion
These studies highlight a novel route of Tat-mediated neuronal damage to induce
motor dysfunction. Loss of KCC2 detection was associated with motor hyperactivity after
two wks of DOX-induced Tat exposure and we found preferential vulnerability of D2Rexpressing MSNs. Importantly, we were able to rescue membrane-localized KCC2 and
behavioral abnormalities with the KCC2 activity enhancer, CLP290, demonstrating the
potential efficacy of KCC2 as a therapeutic target for the treatment of HAND.
The classic striatal model of motor initiation involves a balance between activation
of the D1R-expressing MSN-mediated ‘Go-pathway’ and D2R-expressing MSN-mediated
‘No Go-pathway’ (Gerfen and Young, 1988, Kravitz et al., 2010). Based on this model,
we would expect to have seen a preferential vulnerability of D1R-expressing MSNs to
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Tat-induced KCC2 loss resulting in disinhibition of the D1R-mediated ‘Go pathway’ of
motor initiation. Our data do not support this hypothesis of motor initiation and lend
credence to the growing body of evidence refuting this model. Recent prevailing theories
suggest more subtle circuitry underlying striatal motor initiation and have demonstrated
increased D1R- and D2R-expressing MSN activity during movement (Parker et al., 2018,
Cui et al., 2013, Klaus et al., 2017, Barbera et al., 2016, Kupchik et al., 2015). Thus,
disinhibition of either D1R- or D2R-expressing MSNs may lead to abnormal locomotion
and as our data suggest, D2R-expressing MSN disinhibition induces motor hyperactivity
in the open field assay.
Motor impairment in PWH was initially described in the first publication outlining
neurocognitive decline associated with HIV (Navia et al., 1986) and has persisted into the
era of cART treatment (Valcour et al., 2008, Heaton et al., 2010, Robinson-Papp et al.,
2008). Typically, HIV-induced motor deficits are associated with hypokinetic symptoms
such as bradykinesia (Mirsattari et al., 1998, Bhidayasiri and Tarsy, 2012, Sullivan et al.,
2011, Valcour et al., 2008), but hyperkinetic states like tremor which can be caused by
disinhibition of the striatum (Oran and Bar-Gad, 2018) can be seen as well and may occur
with or without other signs of Parkinsonism (Mirsattari et al., 1998, Cardoso, 2002, Nath
et al., 1987). Our results demonstrate motor hyperactivity after two wks of DOX-induced
Tat exposure (Fig 4.3 A, B) associated with reduced membrane localization of KCC2 (Fig
4.2 C) and may serve as a mechanism underlying heightened striatal output of HIVinduced tremor. Studies utilizing positron emission tomography to measure basal ganglia
metabolism found that early stages of HIV-infection/HAND were associated with
hyperactivity of the basal ganglia, followed by basal ganglia hypometabolism and
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bradykinesia as the disease progresses (von Giesen et al., 2000). Our results with two
wks DOX treatment may represent early disease stages, resulting in excessive striatal
activity caused by hyperactivity in D2R-expressing MSNs of the striatum and increased
locomotion. In fact, we have found that Tat transgenic mice also display a biphasic change
in locomotor activity, whereby, as we have demonstrated here, hyperactivity after two wks
of Tat exposure (Fig 4.3 A, B) and previous studies from our lab found decreased
locomotion after four wks DOX-induced Tat expression (Hahn et al., 2016), a time point
at which we found no differences in KCC2 (Fig 4.1), mirroring the clinical results showing
increased then decreased striatal activation (von Giesen et al., 2000). Importantly, we
also found that we could mitigate Tat-induced motor deficits with pharmacological
maintenance of membrane-bound KCC2 exemplifying the utility of targeting this pathway
as a potential therapy for PWH with motor impairment. Based on the involvement of KCC2
in motor behavior, it is reasonable to hypothesize that KCC2 dysregulation may contribute
to other behavioral or behavioral and cognitive deficits in Tat-transgenic mice and PWH,
respectively, and should be explored going forward. While we found no overt changes in
total KCC2 in the hippocampus, there may be more subtle alterations in specific neuronal
subsets that may not be detectable by western blot of the entire hippocampus and
changes to KCC2 localization and/or function may be present and operative in memory
deficits seen in Tat-transgenic mice and PWH.
Our results should be validated and expanded upon by examining the functional
responses of D1R- and D2R-expressing MSNs by either gramicidin perforated patch
clamp or tight-seal cell-attached current-clamp to measure Cl- reversal and GABAmediated postsynaptic potentials (Perkins, 2006), respectively. We hypothesize that
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D2R-expressing MSNs would preferentially show functional deficits based on our
colocalization results demonstrating selective vulnerability of D2R-expressing MSNs to
Tat-induced KCC2 loss. We previously demonstrated D2R-expressing MSN vulnerability
to Tat-induced decrease in dendritic spine density (Schier et al., 2017). Given the
importance of KCC2 in dendritic spine stability (Fiumelli et al., 2013, Li et al., 2007), and
our results demonstrating D2R-expressing MSN vulnerability to both KCC2 and dendritic
spine loss, future studies should examine whether maintenance of KCC2 with CLP290 is
sufficient to restore dendritic spines. This would further increase the therapeutic scope of
CLP290 for utility in restoration of GABAergic function as well as excitatory circuitry.
Interestingly, we had previously not found significant changes in locomotion in the open
field assay after two wks DOX treatment (Schier et al., 2017). It is important to note that
in our previous studies, we had used Tat+ and Tat- mice crossed with D1-tdTomato and
D2-eGFP mice for all experiments reported in that paper, while the behavioral assays
here utilized Tat+ and Tat- mice (not crossed), potentially suggesting strain differences in
the effects of Tat on locomotion. Previous examinations of D1-tdTomato and D2-eGFP
mice showed no difference and elevated motor activity, respectively, compared to
C57Bl/6 control mice (Ade et al., 2011). Motor hyperactivity found in the D2-eGFP mice
may have confounded data from the open field assay in our previous study, resulting in
the disparate outcomes between the data presented here and those from our earlier study
(Schier et al., 2017). Other subtle differences in experimental paradigm may explain these
differences as well. The behavioral battery in the prior study more intensively explored
anxiety-like behaviors measured with the elevated plus maze on the same day as the
open field assay and differences in assay length: 20 min versus 30 min for the present
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study and previous examinations, respectively. Whether these or other potential
confounds (such as experimenter or prior handling) produced the discrepancies between
these studies should be examined going forward.
HIV infection has many comorbidities including substance use disorder (SUD) and
drug use can affect the progression of HAND (NIDA, 2019, Canan et al., 2018, Denis et
al., 2019, Bell et al., 2002, Byrd et al., 2011). PWH have also been shown to have
disrupted reward processing, placing them at higher risk for adverse outcomes associated
with SUD (Anderson et al., 2016, Plessis et al., 2015). Drugs of abuse have profound
impact on striatal circuitry and can result in long term circuit changes resulting in
dependency (Koob and Volkow, 2010). Our previous work demonstrated that activation
of µ-opioid receptor by morphine can reduce KCC2 in human neurons in vitro (Chapter
3) and previous studies have shown that opiate dependency can induce a GABA switch
from inhibitory to excitatory (Laviolette et al., 2004, Vargas-Perez et al., 2009). While not
directly explored, changes in KCC2 activity may underlie this shift. Fitting et al. (2010)
also demonstrated that opiate exposure can exacerbate Tat-induced striatal dendritic
pathology (Fitting et al., 2010). Given striatal vulnerability to disruption from both HIV and
drugs of abuse, the experiments performed here should be expanded to examine how
drugs of abuse may interact with Tat to affect striatal KCC2, GABAergic function, and
associated behavioral outputs. Further, Tat exposure has increased cocaine induced
motor hyperactivity (Harrod et al., 2008, Paris et al., 2014a). Thus, these factors may
converge to dysregulate KCC2, exacerbating motor hyperactivity.
CLP290 administration had previously been utilized to restore KCC2 Cl- extrusion
and walking in spinal cord injured mice (Chen et al., 2018), morphine-induced
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hyperalgesia in rats (Ferrini et al., 2017), and somatosensory-related behavior after
traumatic brain injury (Lizhnyak et al., 2019). Here, we increased membrane-localized
KCC2 and restored motor activity to baseline levels after two wks of CNS exposure to
Tat. Membrane-localization and degradation of KCC2 is tightly regulated by several
different phosphorylation events. While its efficacy has been well documented, the
mechanism by which CLP290 reestablishes KCC2 activity remains elusive. Our results
suggest that CLP290 rescues KCC2 activity by restoring phosphorylation of S940 to
increase membrane stabilization of KCC2 and, therefore, Cl- extrusion. Whether CLP290
directly interacts with KCC2 to maintain S940 phosphorylation, or if it enhances PKC or
inhibits PP1 to increase or decrease S940 phosphorylation, respectively, is unknown and
should be explored in future studies.
These experiments demonstrate the role of KCC2 in behavioral deficits induced by
CNS exposure to Tat which add to our previous in vitro studies in which we first identified
dysregulation of KCC2 by HIV-1 and the Tat and gp120ADA HIV proteins. KCC2 is
emerging as a key regulator of hyperexcitability in several neurological disorders and the
use of CLP290 has shown promise for pharmacological reintroduction of KCC2 and
rescue of physiological and behavioral deficits. We provided evidence that begins to
uncover the mechanism by which CLP290 reinstates KCC2 activity which had previously
not been described. Overall, we add in vivo biochemical and behavioral evidence to the
utility of targeting KCC2, perhaps with CLP290, as a potential therapy for PWH with
HAND, particularly those with motor impairment.
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Figure 4.1. Two wk DOX-induced Tat expression in Tat+ mice reduced total
striatal KCC2. Analysis of western blot from hippocampus animals administered DOX
for two (p = 0.82, n = 6), four (p = 0.51, n = 6), and eight wks (p = 0.65, n = 7) show
no significant differences between Tat+ and Tat- mice (A). Two wk DOX administration
significantly reduced total KCC2 in the striatum of Tat+ mice compared to Tat- mice
(** p = 0.001, n = 11 – 12) and four wk DOX groups showed no significant differences
(p = 0.28, n = 6). Representative blots showing decreased KCC2 in Tat+ mice
compared to Tat- after two wk DOX treatment (B; right). All KCC2 western blots are
represented as relative intensity to GAPDH normalized to Tat- groups.
91

Figure 4.2. CLP290 administration rescues phosphorylation of S940 and
membrane localization of KCC2. Two-way analysis revealed a main effect of Tat
expression to reduce total KCC2 (**, p < 0.01, n = 12 – 18) suggesting that CLP290
failed to rescue total KCC2 levels (A). Examination of phosphorylation of S940
revealed a significant decrease in the Tat+/Vehicle group compared to control (** p <
0.01, n = 8 – 12) and rescue with CLP290 (* p < 0.05, n = 8 – 12) (B) suggesting that
membrane bound KCC2 may be altered, which was confirmed by western blot on from
membrane fractionation (** p < 0.01; *p < 0.05, n = 8 – 9) (C). Blots for total and pS940KCC2 are represented as intensity relative to GAPDH normalized to Tat-/Vehicle
controls (A, B). Blots for membrane bound KCC2 are relative to total lane protein
normalized to controls (C).
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Figure 4.3. Tat+ mice show hyperactive locomotion in the open field assay with
CLP290 able to rescue this effect. Tat+ mice given vehicle showed increased motor
activity compared to controls in the open field assay measured by both total distance
travelled (A) and rearing number (B) (**, p < 0.01, n = 8 – 9). CLP290 administration
significantly decreased total distance travelled and rearing number in Tat+ mice (*, p
> 0.05, n = 8 – 9), suggesting that restoration of membrane-localized KCC2 was
sufficient to rescue abnormal locomotor activity in these animals. We also examined
time spent in center zone as a measure of anxiety-like behavior and found no
significant differences (n = 8 – 9) (C).
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Figure 4.4. D2R-expressing MSNs display Tat-induced KCC2 loss while D1Rexpressing MSNs do not. Colocalization analyses revealed no change in KCC2
immunofluorescence with tdTomato between Tat+ x Drd1a-tdTomato and Tat- x
Drd1a-tdTomato mice (n = 3 (Tat-), 12 (Tat+)) (A, B). Representative images showed
no change in KCC2 immunofluorescence in D1R-expressing MSNs (tdTomato).
Yellow arrows exemplify somatic KCC2 staining, localized around the cell membrane,
in D1R-expressing MSNs (A). Tat+ x Drd2-eGFP mice showed decreased
colocalization with KCC2 immunofluorescence compared to Tat- x Drd2-eGFP mice
(*p < 0.05; n = 8) (C, D). Representative images showed strong colocalization in D2Rexpressing

MSNs

of

Tat-

mice,

while

Tat+

mice

showed

decreased

immunofluorescence colocalized with D2R-expressing MSNs (eGFP) (C). Yellow
arrows exemplify somatic membrane KCC2 colocalization with D2R-expressing MSNs
(top C). White arrows exemplify D2R-expressing neurons with reduced KCC2 cell
membrane localization and decreased colocalization with eGFP (bottom C). These
results suggest a preferential vulnerability of D2R-expressing MSNs to Tat-induced
KCC2 loss. Scale bar = 20 µM.
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Chapter 5
Conclusions and Future Directions

The introduction of cART has changed the prognosis of an HIV-1 infection from a
virtual death sentence to a manageable chronic condition. Thus, the focus of treatments
for these patients has shifted from prophylaxis against opportunistic infection to viral
suppression and improvement of quality of life. Even with cART adherence, HAND is a
preeminent complication for up to 50% of PWH (Heaton et al., 2010). Neuronal
hyperexcitability along with reduced synaptodendritic complexity underlies disrupted
circuitry that manifests as cognitive and behavioral alterations associated with HAND
(Masliah et al., 1997). Heightened glutamatergic signaling plays a significant role and has
classically been the center of focus when studying hyperexcitability. Mounting evidence
also demonstrates disrupted GABAergic signaling as a vital component to this process
(Gelman et al., 2012a, Buzhdygan et al., 2016). The evidence presented in this
dissertation demonstrates that KCC2 plays an integral role in disrupting the postsynaptic
response in GABAergic signaling, contributing to hyperexcitability of the HIV-exposed
CNS. Through experiments involving a novel human in vitro model and DOX-inducible,
GFAP-driven Tat-transgenic mice we determined that HIV-1, and viral proteins diminish
KCC2 resulting in GABAAR signaling deficits and behavioral abnormalities. Most of these
deficits were ameliorated pharmacologically using the KCC2 enhancer, CLP257, and its
prodrug, CLP290, demonstrating the efficacy of targeting KCC2 as a novel therapy for
HAND.
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SUD is a common comorbidity of HIV-infection. IDU was responsible for ~20% of
new HIV-1 cases in 2016 and up to 50% of PWH are prescribed opiates (NIDA, 2019,
Denis et al., 2019, Chilunda et al., 2019). Regardless of whether use is illicit or prescribed,
opiate exposure results in faster progression of AIDS (Peterson et al., 1990, Peterson et
al., 2004), and possibly, exacerbated HAND symptomology (Bell et al., 2002, Bell et al.,
1998, Byrd et al., 2011, Chiesi et al., 1996, Lucas et al., 2006). These enhanced
symptoms are likely the result of cellular signaling convergence from HIV proteins and
opiate activation of MOR in areas of the brain vulnerable to insult from both factors, such
as the hippocampus and striatum. Previously identified targets of morphine-HIV neuronal
signaling convergence include GSK3β (Masvekar et al., 2015), and p38 mitogen activated
protein kinases (MAPK) (Mukerjee et al., 2008, Hu et al., 2005) which can enhance
neuronal death in vitro. Our results demonstrate that morphine activation of MOR can
independently reduce KCC2 and disrupt GABAAR-mediated hyperpolarization and
inhibition and has a significant or trend toward a combinatorial effect with HIV-Tat and
gp120, respectively, to enhance KCC2 loss under certain conditions (Chapter 3; Fig 3.1,
3.2, 3.4, 3.5, 3.6). Thus, our in vitro results provide a cellular/molecular substrate upon
which opiates disrupt GABA signaling and can converge with HIV protein-mediated
pathways to enhance these effects.
Opiate administration activates MOR on GABAergic interneurons of the VTA,
inhibiting GABA release from this neuronal subpopulation, thus, disinhibiting DAergic
neurons, increasing DA release on the NAcc inducing feelings of euphoria and promoting
opiate dependence. Previous studies have demonstrated that opiate dependence and
withdrawal cause a switch of GABA on VTA GABAergic terminals from inhibitory to
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excitatory, although they did not provide a mechanistic cause of this physiological reversal
(Laviolette et al., 2004, Vargas-Perez et al., 2009). Our results provide the first direct link
between MOR activation and diminished KCC2 and neuronal disinhibition (Chapter 3; Fig
3.1, 3.6). Thus, it is feasible that MOR activation after repeated exposures to opiates in
vivo results in decreased KCC2 on GABAergic interneurons of the VTA. This, in turn,
necessitates continual MOR activation to maintain their inhibition (through neuronal Gi/o
signaling) thereby maintaining VTA DAergic activity, which would promote opiate
dependency. Removal of MOR activation disinhibits these GABAergic interneurons,
which is now exacerbated by reduced KCC2 and GABAAR-mediated excitation and thus,
strongly inhibits VTA DAergic neuronal activity on the NAcc inducing a withdrawal state.
This proposed mechanism of KCC2-driven opiate dependency and withdrawal should be
investigated in vivo to determine if opiate dependency and withdrawal reduce KCC2 in
GABAergic interneurons of the VTA and if modulation (perhaps with CLP290) affects
outcomes associated with excitatory GABA and opiate dependency and withdrawal.
Signaling from HIV and drugs of abuse converge on the striatum and studying their
interactive effects may give insight to the vulnerability of PWH to reward deficits. These
deficits have been reflected in studies in which Tat+ mice showed a three-fold increase
in both ethanol and cocaine conditioned place preference (CPP) compared to controls
(Paris et al., 2014a, McLaughlin et al., 2014). These behavioral changes are
accompanied by significant changes in DAergic markers (Kesby et al., 2016, Ferris et al.,
2009a, Ferris et al., 2009b) and drug of abuse enhancement of striatal MSN damage
(Fitting et al., 2010, Bruce-Keller et al., 2008). Classic theories on reward circuitry,
typically studied in regard to drugs of abuse, proposed a diametrically opposed role of
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D1R and D2R-expressing MSNs. D1R-expressing MSNs theoretically encode reward and
are activated by drugs of abuse and whose stimulation can induce/potentiate CPP,
whereas D2R-MSNs encode aversion and inhibit drugs of abuse-induced CPP (Lobo et
al., 2010, Hikida et al., 2010, Tai et al., 2012, Kravitz et al., 2012). This controversial
theory of reward circuitry has come into question in more recent studies (Soares-Cunha
et al., 2016, Natsubori et al., 2017, Cole et al., 2018) exemplified by a 2019 publication
that demonstrated that both D1R and D2R-expressing MSNs can encode reward,
dependent on neuronal stimulation frequency, determined by selective optogenetic
activation of D1R and D2R-expressing MSNs (Soares-Cunha et al., 2019). Our data
suggests GABAergic disruption in the striatum of Tat+ mice, specifically, disinhibition of
D2R-expressing MSNs is mediated through reduced KCC2 (Chapter 4, Fig 4.3, 4.4).
These may be involved in the sequelae of events resulting in Tat-potentiated cocaine and
ethanol reward salience and reward deficits in PWH. Future studies should examine if
modulation/restoration of GABAergic inhibition of D2R-expressing MSN could ameliorate
Tat-potentiated CPP.
It is important to note the hNeuron in vitro model described in Chapter 2 and utilized
in Chapter 3 is a mixed neuron-glia (astrocyte) co-culture. Thus, it may be direct neuronal
MOR activation or activation of MOR on glia, which through an unknown mediator, acts
on neurons to diminish KCC2. Ferrini et al (Ferrini et al., 2013) demonstrated that
morphine-induced KCC2 reductions in the spinal cord induce hyperalgesia and were
mediated by microglial purinergic receptor activation. Additionally, previous studies in our
lab have rarely found interactions between HIV proteins and opiates in vitro with less than
24 h exposures and combinatorial effects from these factors at later time points are
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consistently mediated by glia (Zou et al., 2011, Kim et al., 2018). When taken together
with our results showing morphine-Tat interactions at 24 h, but not at 6 h, it may be that
morphine-induced KCC2 loss is glial-mediated (Fig 5.1).
The role of KCC2 dysregulation has been investigated in several neurological
disorders (outlined in Chapter 1) and we are the first to demonstrate its role in neuroHIV
(Chapters 3, 4). While these neurodegenerative disorders have different etiologies, there
are several common hallmarks between them such as neuroinflammation and elevated
glutamatergic signaling. Another emerging commonality is neuronal Cl- gradient collapse
via reduced KCC2 activity, resulting in neuronal disinhibition through diminished
GABAAR- mediated hyperpolarization and inhibition, and in some cases, GABAARmediated depolarization and excitation. While there are common pathways, the cognitive
and behavioral consequences are often vast. These differences arise in age of onset,
brain regions and neuronal subsets affected, white matter involvement, and differences
in immune recruitment, among others. For example, Rett Syndrome has large-scale
behavioral and cognitive abnormalities compared to those typically seen with HAND.
These differences arise in their separate etiologies: Rett is a genetic disorder and, thus,
these KCC2 deficits result in improper GABAergic tuning during a critical period of CNS
development (as well as other cellular and molecular sequelae differences), resulting in
large-scale cognitive deficits. HIV is typically acquired after these critical periods of
development, and, thus, the deficits of HAND are comparatively, subtle. Loss of KCC2
function has a well-established link to epilepsy via neuronal disinhibition, but seizures are
not always seen in states of lowered KCC2 and while the rates of epilepsy due to HIV
infection (~4%) are higher than the general population (1.2%), they are still low
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(Kellinghaus et al., 2008). The involvement of KCC2 in epileptogenesis is likely due to
extent of KCC2 activity loss and brain regions and neuronal subsets affected. Extreme
loss of KCC2 activity may result in accumulation of [Cl-]i to the point of Cl- efflux upon
GABAAR activation resulting in depolarization, and possibly neuronal excitation. The
subsets of neurons affected have drastic effects on neuronal micro- and macro-circuitry.
For example, ablation of KCC2 in pyramidal neurons of the hippocampus resulted in
GABAAR-mediated depolarization and was sufficient to induce temporal lobe epilepsy
(Kelley et al., 2018). In contrast, our results suggest that HIVsup ± morphine-induced KCC2
activity loss are not as profound, as there is still hyperpolarization due to GABAAR
activation (Fig 3.2). Our in vivo data showed KCC2 loss in D2R-expressing MSNs of the
striatum, but we found no overt loss of KCC2 in the hippocampus (Fig. 4.1, 4.4) and while
Tat+ mice have displayed lower kainite-evoked seizure thresholds (Zucchini et al., 2013),
epilepsy has not been noted in Tat-transgenic mice. Thus, HIV exposure may be
associated with KCC2 loss and hyperexcitability, but the development of epilepsy
depends on differences in extent of [Cl-]i accumulation and neuronal subsets and brain
regions with reduced KCC2 activity. Despite differing etiologies, neuronal subpopulation
and brain region involvement, and cognitive/behavioral consequences, the commonalities
underlying the neuropathology of these disorders suggest that there may be common
therapies between them.
CLP257 and its prodrug, CLP290, are capable of maintaining membrane
expression of KCC2, and thus maintain neuronal Cl- extrusion, but the mechanism
underlying these effects has yet to be elucidated. We demonstrated its utility in vitro in
maintaining KCC2 immunoreactivity and GABAAR-mediated hyperpolarization and
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inhibition after exposure to HIVsup, Tat, and morphine exposure (Chapter 3, Fig 3.1, 3.2,
3.4, 3.5, 3.6). In vivo studies found that CLP290 could restore KCC2 and GABAergic
activity to reactivate neuronal circuitry after spinal cord injury reinstating walking (Chen et
al., 2018), restore somatosensation after TBI (Lizhnyak et al., 2019), and reverse
morphine induced hyperalgesia (Ferrini et al., 2017). We found that daily oral gavage of
CLP290 for seven days during the second week of DOX treatment was capable of
ameliorating abnormal motor activity in Tat+ mice (Chapter 4, Fig 4.4). While unable to
rescue total KCC2 levels, CLP290 administration did rescue pS940-KCC2, and
membrane localized KCC2, suggesting rescued neuronal Cl- gradient and proper
GABAergic transmission (Chapter 4, Fig 4.3). These results also provide insight to a
possible mechanism that CLP290 acts. Our results demonstrate that CLP290 rescues
membrane localization of KCC2 through maintenance of pS940. Although whether
CLP290 interacts directly with KCC2 to prevent PP1 dephosphorylation of KCC2, inhibits
PP1 itself, enhances PKC phosphorylation of S940, or modulates activity upstream of
PP1 or PKC is unknown. It is also possible that CLP290 maintains other phosphorylation
states important for membrane localization/degradation and these phosphorylation
specific residues should be examined going forward. Our results demonstrated a failure
of CLP257 to restore KCC2 and GABAAR-mediated inhibition after exposure to gp120ADA
(Chapter 3, Fig 3.5, 3.6). Taken together with our data implicating involvement of pS940
in CLP290s mechanism of action, suggests that gp120ADA may dysregulate pathways
involved in the mechanism of action of CLP290.
The primary therapy for HAND is viral suppression via cART. Since its introduction,
there has been a reduction of the most severe form of HAND, HAD, but there has been
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an increase in the two milder forms with an overall prevalence remaining the same
(Heaton et al., 2010). While able to control viral loads in the periphery, the CNS can act
as a reservoir for HIV which may play a role in the persistence of HAND. Other factors
that may be implicated in continuing neurocognitive detriment include an aging HIV
population and, potentially, neurotoxic effects from some ARVs. Regardless of the cause,
this preeminent quality of life issue for PWH underscores the necessity for adjuvant
therapies to ameliorate the symptoms of HAND. As the preeminent theories for neuronal
dysfunction in HAND centered around glutamatergic and Ca2+ signaling, so did trials for
adjuvant therapies. Trials for NMDAR antagonist, memantine, and voltage gated L-Type
Ca2+ channel, nimodipine had little to no success at restoring or decelerating deficits of
HAND (Schifitto et al., 2007, Navia et al., 1998). Other adjuvant therapies to reach clinical
trial have been a monoamine oxidase B inhibitor, selegiline, (Sacktor et al., 2009), TNF
antagonist, CPI-1189 (Clifford et al., 2002) an acetylcholinesterase inhibitor, rivastigmine
(Sacktor et al., 2011), and valproic acid (Schifitto et al., 2006), none of which significantly
improved symptoms of HAND. Going forward, targeting KCC2, perhaps with CLP290 may
prove to be beneficial to restore GABAergic inhibition and ameliorate the excitatoryinhibitory imbalance of the HIV-exposed CNS as discussed thoroughly in chapters 3, 4,
and 5. At this time, CLP290 has not been tested in clinical trials. Bumetanide, a diuretic
that is approved for clinical use, has been shown to restore neuronal Cl- gradient via
antagonism of NKCC1. Acting in opposition to KCC2, NKCC1 increases neuronal [Cl-]i, is
the dominant neuronal Cl- transporter in the immature brain and is aberrantly increased
in some neurological disorders. Clinically, bumetanide significantly reduced seizure
frequency in temporal lobe epilepsy (Eftekhari et al., 2013) and benefited neurocognitive
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and behavioral outcomes for those suffering from drug-resistant epilepsy (Gharaylou et
al., 2019), autism (Lemonnier and Ben-Ari, 2010, Lemonnier et al., 2012, Lemonnier et
al., 2017), and schizophrenia (Lemonnier et al., 2016) through restoration of inhibitory
GABAergic signaling. While we saw no changes in NKCC1 in our in vitro experiments,
future studies should examine NKCC1 changes in Tat transgenic mice and human tissue
to determine if this could be a potential adjuvant therapy for PWH experiencing
neurocognitive decline.
Our discovery that CCR5 mediates KCC2 immunoreactivity and inhibitory effects
of GABA (Chapter 3; Fig 3.5, 3.6) is a novel mechanism of neuro-immune interaction and
may have implications for PWH as well as other neuroinflammatory disorders. MVC, an
FDA approved CCR5 antagonist, is a commonly prescribed ARV to prevent viral entry
with high CNS penetrance (Yilmaz et al., 2009). A clinical study found that when MVC
use was intensified, PWH with neurocognitive impairment had significant improvements
in global functioning, learning and memory, and executive function (Ndhlovu et al., 2014).
Thus, restored KCC2 and GABAergic hyperpolarization may be a molecular and
physiological mechanism underlying improvements in these subjects. To our knowledge,
this is the first time a chemokine receptor has been linked to changes in KCC2. This route
of neuro-immune crosstalk demonstrates a novel pathway by which immune activation
can fine-tune neuronal circuitry and induce hyperexcitability and, therefore, may be
involved in other disorders that show operative CCR5-CCL5 signaling. For example,
multiple sclerosis increases CCL5 (Sorensen et al., 1999). Of particular relevance, one
study with multiple sclerosis patients used a paired pulse transcranial magnetic
stimulation (TMS) protocol to induce intracortical inhibition (inter stimulus interval of 2
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ms), which is GABAAR mediated (Di Lazzaro et al., 2006), and found decreased paired
pulse-induced cortical inhibition was significantly correlated with subjects CSF CCL5
levels (Mori et al., 2016). Thus, these results may be explained by decreased GABAAR
inhibition via increased CCR5 activation and subsequent reduction in KCC2 activity.
Given this novel CCR5-KCC2 signaling cascade, MVC should be considered more
heavily for PWH experiencing neurocognitive decline and should be examined for use in
other disorders in which elevated CCL5-CCR5 signaling is a component of
neuroinflammation.
D2R-expressing MSNs seem to be particularly vulnerable to hyperexcitability
(Cepeda et al., 2008) and excitotoxicity through glutamate receptor activation (Mesco et
al., 1992). Previous studies from our lab have demonstrated vulnerability of striatal
neurons, particularly D2R-expressing MSNs, of Tat+ mice to dendritic spine loss induced
by elevated [Ca2+]i (Fitting et al., 2014, Fitting et al., 2010, Schier et al., 2017). KCC2
interactions with cytoskeletal elements to maintain dendritic spines and our results
showing Tat-induced, NMDAR-dependent KCC2 loss (Fig 3.1, 3.4), suggest that the Tatinduced neuropathology (dendritic spine and KCC2 loss) noted between these studies
may be part of the same signaling cascade. We propose that Tat-mediated NMDARdependent [Ca2+]i elevation induces dephosphorylation of S940 and KCC2 internalization
and degradation, preferentially in D2R-expressing MSNs, destabilizing and ultimately
reducing dendritic spine density. Thus, Tat induction induces striatal inhibitory and
excitatory dysfunction through KCC2 reduction and subsequent dendritic spine loss,
respectively. These interactions should be examined by determining if KCC2
maintenance (with CLP290) is sufficient to restore dendritic spines on D2R-expressing
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MSNs which may also broaden the therapeutic potential of targeting KCC2 with drugs like
CLP290.
While motor disorders associated with HAND typically involve hypokinetic states,
such as bradykinesia, our results demonstrate hyper locomotion in the open field assay
after two wks DOX treatment. These seemingly paradoxical results may actually reflect
the biphasic nature of striatal activation and motor impairment seen in PWH (von Giesen
et al., 2000). Early in disease progression, subjects showed hypermetabolism of the
striatum measured by positron emission tomography, while in more advanced stages of
HIV infection subjects showed striatal hypometabolism and motor slowing. When taken
together, the behavioral results presented in this dissertation showing increased motor
activity after two wks of DOX-induced Tat expression (Fig 4.3) and previous work form
our lab demonstrating decreased locomotion after 4 wk DOX treatment, reflect the
progression of motor changes in PWH. Further, these locomotor changes also follow the
biphasic response of KCC2 loss examined in Chapter 4 (Fig 4.1, 4.2). In accordance with
decreased KCC2 in D2R-expressing MSNs (and, therefore, likely disinhibition of these
cells), there is an increase in motor activity and as we see a recovery of KCC2 to baseline
levels at four wk DOX-induced Tat exposure, there is a reversal in motor effects to
hypolocomotion in the open field assay (Hahn et al., 2016). These results stand in
contradiction to the classic ‘Go/ No Go’ theory of striatal motor activation and support
emerging evidence showing that either D1R- or D2R-expressing MSN activation are
implicated in motor initiation which is covered in the discussion of Chapter 4. Overall, we
propose that the increased striatal output seen early in disease progression in PWH may
be a result of decreased striatal KCC2 (preferentially in D2R-expressing MSNs), resulting
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in neuronal disinhibition, thus increasing striatal activity, and as KCC2 returns to baseline,
giving way to more prolonged circuit changes and DA depletion, there is a reversal of
striatal activity manifesting as hypokinesia, resulting in the striatal hypometabolism and
Parkinsonian-like states described clinically.

Final Conclusion
The work performed for this dissertation described two in vitro models with
particular utility for HAND, one of which we used to identify a novel target of HIV and
opiates to disrupt GABAergic signaling. Pharmacological manipulation of this novel target,
KCC2, with CLP257 restored GABAAR-mediated hyperpolarization and inhibition. In vitro
experiments performed in Chapter 3 have implications beyond the neuroHIV and drug
abuse fields. We identified CCR5-KCC2 as a novel intermediary of neuro-immune
interaction by which chemokine receptor signaling can disrupt GABAAR activity.
Additionally, these studies demonstrated that morphine activation of MOR decreases
KCC2, and may provide insight to the molecular substrate implicated in the synchrony of
events resulting in GABAergic reversals in opiate-dependent animals. We expanded our
in vitro KCC2 results to the Tat-transgenic mouse and found reduced striatal KCC2 after
two wks of Tat expression. Additionally, D2R-expressing MSNs of the striatum seem to
be preferentially vulnerable to KCC2 loss and these changes were associated with hyper
locomotion. We were able to restore basal motor activity and membrane localized KCC2
through rescue of phosphorylation of S940-KCC2 with CLP290 oral gavage, providing
insight to a potential mechanism by which this drug works. In total, the studies presented
describe a promising therapeutic target for HAND and implicate a common mechanism
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between HIV proteins and morphine to dysregulate GABAergic activity, which may have
additional relevance in opiate abusing populations.
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Figure 5.1. Mechanisms underlying Tat, gp120ADA, and morphine-induced KCC2
loss and GABAAR dysfunction.
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Education
Virginia Commonwealth University
August 2014- Present (Expected Graduation Spring 2020)
Neuroscience PhD Candidate
GPA: 3.9

Virginia Polytechnic Institute and State University
Graduation Date: May, 2012
B.S., Biological Sciences, Psychology

Research Experience
Graduate Research Associate, Virginia Commonwealth University, Advisor: Dr. Pamela E.
Knapp
August 2014 - Present
KCC2: a novel therapeutic target to rescue GABAergic dysfunction and behavioral deficits
induced by HIV and opiate use
∙ Genetically encoded voltage (FlicR1, Archon1) and calcium (GCaMP6f) indicators
∙Rig construction
∙Transfection/infection (chemical and AAV)
∙Recording
∙Custom analysis in R
∙ Human cell line differentiation and culture techniques
∙ Development of primary human neuron differentiation protocol
∙ Human brain organoid culture techniques and characterization
∙ Mouse handling and surgical techniques
∙ Mouse behavioral assays and analysis (ANY-maze™)
∙ Mouse neuron and mixed glia culture techniques
∙ Fluorescent immunocytochemistry and immunohistochemistry
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∙ Confocal laser scanning microscopy
∙ 3-D neuron reconstruction and morphological analysis (Imaris)
∙ Polymerase chain reaction (PCR)
∙ Enzyme-linked immunosorbent assay (ELISA)
∙ Western Blot
Research Technician, Virginia Tech Carilion Research Institute, Advisor: Dr. William. J. Tyler
August 2012- March 2014
∙ Collected data using EEG, fMRI, ECG, MEPs, fNIRS, GSR, neuronavigation
∙ Administered noninvasive neurostimulation protocols using TMS, tDCS, tACS, tFUS
∙ Analyzed EEG, ECG, MEP, fMRI, and behavioral data using Matlab, SPM8, BrainVision™,
Spike 2™
Teaching Experience

Private Chemistry Tutor, Blacksburg, VA
August 2011- August 2012

Publications
Barbour AJ, Nass SR, Hahn YK, Hauser KF, Knapp PE. Restoration of KCC2
membrane localization in striatal D2R-expressing medium spiny neurons
rescues behavioral deficits in HIV Tat-transgenic mice. In preparation.
Marks WD, Paris JJ, Barbour AJ, Moon J, McClane VD, Lark A, Nass SR, McQuiston
AR, Knapp PE, Hauser KF. The effects of Tat and morphine on the structure and
function of CA1. In preparation.
Barbour AJ, Hauser KF, McQuiston AR, Knapp PE (2020). HIV and opiates
dysregulate KCC2 to cause GABAergic dysfunction in primary human neurons.
Article accepted, in press. Neurobiology of Disease.
Schier CJ, Marks WD, Paris JJ, Barbour AJ, McQuiston AR, Knapp PE, Hauser KF
(2017). HIV-1 Tat causes selective vulnerability of D2-expressing medium spiny neurons.
Journal of Neuroscience, 37 (23):5758-69.
Opitz A, Legon W, Mueller J, Barbour AJ, Paulus W, Tyler WJ (2015). Is sham cTBS
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real cTBS? The effect on EEG dynamics. Frontiers of Human Neuroscience. doi:
10.3389/fnhum.2014.01043.
Legon W, Sato TF, Opitz A, Mueller J, Barbour AJ, Williams A, Tyler WJ (2014).
Modulation of human brain circuits by transcranial focused ultrasound. Nature
Neuroscience, 17(2):322-9. doi:10.1038/nn.3620
Invited Talks
Local
HIV and HIV proteins ± morphine dysregulate KCC2 inducing GABAergic deficits in
primary human neurons and Tat-transgenic mice. VCU Department of Anatomy &
Neurobiology Seminar Series. 2019.

National Meetings
HIV and morphine induce GABAergic deficits through dysregulation of KCC2.
Nanosymposium - HIV-associated neurocognitive disorders. Society for
Neuroscience, Chicago, IL. 2019.

Optical electrophysiology of primary human neurons: role of KCC2 in hyperexcitability
induced by HIV ± morphine exposure. Presentation of selected abstracts. American
Society for Neurochemistry, Riverside, CA. 2018.

Abstracts
Barbour AJ, McQuiston AR, Hauser KF, Knapp PE (2019). HIV and morphine
dysregulate KCC2 and induce GABAergic deficits in neurons via NMDAR,
CCR5, and MOR. International Society for Neurochemistry – American Society
for Neurochemistry, Montreal, QC, Canada.
Barbour AJ, Balinang J, McQuiston AR, Hauser KF, Knapp PE (2018). HIV-1 & HIV
proteins interact with morphine to induce loss of KCC2 & GABAergic dysfunction
in primary human neurons in a NMDAR & CCR5 dependent manner. Society for
Neuroscience, San Diego, CA.
Barbour AJ, Balinang J, McQuiston AR, Hauser KF, Knapp PE (2018). Optical
electrophysiology of primary human neurons: role of KCC2 in hyperexcitability
induced by HIV ± morphine exposure. International Society of
Neurovirology/Society for NeuroImmune Pharmacology, Chicago, Il.
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Barbour AJ, Balinang J, McQuiston AR, Hauser KF, Knapp PE (2017). Optical
electrophysiology of human primary neurons: role of KCC2 in excitatoryinhibitory imbalance induced by HIV ± morphine exposure. Society for
Neuroscience, Washington, DC.
Moon J, Marks WD, Barbour AJ, Knapp PE, Hauser KF (2017). HIV-1 Tat causes
selective reductions in dendritic spines in the stratum oriens and the stratum
radiatum, but not the stratum lacunosum moleculare of hippocampal CA1
pyramidal cells. Society for Neuroscience Washington, DC.
Marks WD, Barbour AJ, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR,
Knapp PE, Hauser KF (2016). HIV-1 Tat causes structural abnormalities in CA1
regional microcircuitry, and disturbances in CA1 function and memory formation.
Platform talk (Marks). Society for Neuroscience, San Diego, CA.
Marks WD, Barbour AJ, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR,
Knapp PE, Hauser KF (2016). Interaction between HIV-1 Tat and morphine
causes disruption of GABAergic systems within CA1. International Symposium
on Neurovirology, Toronto, Ontario, Canada.
Schier CJ, Marks WD, Paris JJ, Barbour AJ, McQuiston AR, Knapp PE, Hauser KF
(2016). CNS effects of opiate exposure in a mouse model of NeuroAIDS:
selective vulnerability of D1 and D2-expressing medium spiny neurons.
American Society for Neurochemistry, Denver, CO.
Opitz A, Legon W, Mueller J, Barbour AJ, Bickel W, Paulus W, Tyler WJ (2014).
Weak electric field effects from sham transcranial magnetic stimulation over the
dorsolateral prefrontal cortex on EEG dynamics and working memory.
Biomedical Engineering Society. San Antonio, TX.
Lofti M, Legon W, Barbour AJ, Williams A, Tyler WJ (2013). Neurophysiological
responses to short duration transcranial direct current stimulation of human
prefrontal cortex. Society for Neuroscience. San Diego, CA.
Legon W, Barbour AJ, Tyler W, Williams A, Opitz A, Tyler WJ (2013). Transcranial
ultrasound modulates human brain activity. Human Brain Mapping. Seattle,
WA.
Opitz A, Legon W, Mueller J, Barbour AJ, Williams A, Paulus W, Tyler WJ (2013).
Effects of the residual electric field induced by sham coils should not be
neglected in TMS studies. Human Brain Mapping. Seattle, WA.
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Professional Memberships

Society for Neuroscience

International Society for Neurochemistry - American Society for Neurochemistry

Awards
MVC Alumni Association Scholarship.
2020
Ruth L. Kirchstein National Research Service Award (NRSA) Individual Predoctoral
Fellowship (F31). National Institute of Drug Abuse (NIDA). F31DA047195.
2018-2019
Phi Kappa Phi Scholar Award (for outstanding academic performance). School of
Medicine, Virginia Commonwealth University.
2018
C.C. Clayton Award (for outstanding academic and research progress in the
biomedical sciences). School of Medicine, Virginia Commonwealth University.
2017
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